WO2024064026A1 - Modulateurs d'akt1 - Google Patents
Modulateurs d'akt1 Download PDFInfo
- Publication number
- WO2024064026A1 WO2024064026A1 PCT/US2023/032870 US2023032870W WO2024064026A1 WO 2024064026 A1 WO2024064026 A1 WO 2024064026A1 US 2023032870 W US2023032870 W US 2023032870W WO 2024064026 A1 WO2024064026 A1 WO 2024064026A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- solvate
- compound
- pyridin
- Prior art date
Links
- 101150045355 akt1 gene Proteins 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 195
- 150000001875 compounds Chemical class 0.000 claims abstract description 185
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims abstract description 75
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims abstract description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims description 160
- 239000012453 solvate Substances 0.000 claims description 138
- 229910052736 halogen Inorganic materials 0.000 claims description 107
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 70
- 229910052739 hydrogen Inorganic materials 0.000 claims description 62
- 239000001257 hydrogen Substances 0.000 claims description 62
- 229910052757 nitrogen Inorganic materials 0.000 claims description 55
- 125000003107 substituted aryl group Chemical group 0.000 claims description 53
- 150000002431 hydrogen Chemical group 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 49
- 125000000623 heterocyclic group Chemical group 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 16
- 229910052805 deuterium Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical group 0.000 claims description 16
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 15
- 230000001613 neoplastic effect Effects 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 abstract description 6
- -1 -CN radical Chemical class 0.000 description 1171
- 239000000543 intermediate Substances 0.000 description 392
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 258
- 238000005160 1H NMR spectroscopy Methods 0.000 description 214
- 239000007787 solid Substances 0.000 description 207
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 192
- 239000000203 mixture Substances 0.000 description 170
- 238000006243 chemical reaction Methods 0.000 description 150
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 141
- 230000002829 reductive effect Effects 0.000 description 128
- 239000011541 reaction mixture Substances 0.000 description 108
- 239000000243 solution Substances 0.000 description 102
- 125000005843 halogen group Chemical group 0.000 description 101
- 239000007832 Na2SO4 Substances 0.000 description 98
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 98
- 229910052938 sodium sulfate Inorganic materials 0.000 description 98
- 238000002953 preparative HPLC Methods 0.000 description 97
- 235000019439 ethyl acetate Nutrition 0.000 description 95
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 92
- 239000012044 organic layer Substances 0.000 description 90
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 84
- 239000012267 brine Substances 0.000 description 83
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 83
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 77
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 68
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 68
- 239000003480 eluent Substances 0.000 description 64
- 150000003840 hydrochlorides Chemical class 0.000 description 62
- 238000003818 flash chromatography Methods 0.000 description 60
- 239000012071 phase Substances 0.000 description 60
- 239000000741 silica gel Substances 0.000 description 60
- 229910002027 silica gel Inorganic materials 0.000 description 60
- 235000011152 sodium sulphate Nutrition 0.000 description 54
- 239000007858 starting material Substances 0.000 description 54
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 53
- 125000002947 alkylene group Chemical group 0.000 description 53
- 230000000875 corresponding effect Effects 0.000 description 50
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 49
- 125000004432 carbon atom Chemical group C* 0.000 description 49
- 239000003208 petroleum Substances 0.000 description 42
- 150000003254 radicals Chemical class 0.000 description 37
- 125000000217 alkyl group Chemical group 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- NXZBZWZORYEIJL-UHFFFAOYSA-N 3-formyl-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(C=O)=C1 NXZBZWZORYEIJL-UHFFFAOYSA-N 0.000 description 34
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 32
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 30
- 239000003643 water by type Substances 0.000 description 30
- 125000004450 alkenylene group Chemical group 0.000 description 29
- FDDHFCWYCKQKGY-UHFFFAOYSA-N 4-formyl-3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C(O)=C1 FDDHFCWYCKQKGY-UHFFFAOYSA-N 0.000 description 28
- 239000012299 nitrogen atmosphere Substances 0.000 description 27
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 25
- 108091008611 Protein Kinase B Proteins 0.000 description 24
- 239000000126 substance Substances 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 23
- 125000004419 alkynylene group Chemical group 0.000 description 23
- 125000003118 aryl group Chemical group 0.000 description 22
- 239000012043 crude product Substances 0.000 description 22
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 20
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 20
- 239000008176 lyophilized powder Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 229910052799 carbon Inorganic materials 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 238000000746 purification Methods 0.000 description 15
- NXMFJCRMSDRXLD-UHFFFAOYSA-N 2-aminopyridine-3-carbaldehyde Chemical compound NC1=NC=CC=C1C=O NXMFJCRMSDRXLD-UHFFFAOYSA-N 0.000 description 14
- 229910004878 Na2S2O4 Inorganic materials 0.000 description 14
- 125000003709 fluoroalkyl group Chemical group 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 229910017906 NH3H2O Inorganic materials 0.000 description 12
- 125000003710 aryl alkyl group Chemical group 0.000 description 12
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 12
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 125000004093 cyano group Chemical group *C#N 0.000 description 11
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 11
- 102200093329 rs121434592 Human genes 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 10
- 229910000024 caesium carbonate Inorganic materials 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 238000004293 19F NMR spectroscopy Methods 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 125000004043 oxo group Chemical group O=* 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 125000005884 carbocyclylalkyl group Chemical group 0.000 description 7
- 125000004431 deuterium atom Chemical group 0.000 description 7
- 150000002430 hydrocarbons Chemical group 0.000 description 7
- 125000001841 imino group Chemical group [H]N=* 0.000 description 7
- IGPIVTOCMFBYMS-UHFFFAOYSA-N methyl 4-[(6-chloro-3-nitropyridin-2-yl)amino]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1NC1=NC(Cl)=CC=C1[N+]([O-])=O IGPIVTOCMFBYMS-UHFFFAOYSA-N 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 125000000547 substituted alkyl group Chemical group 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 229910006124 SOCl2 Inorganic materials 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 6
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- HURFXWYAABUPFZ-UHFFFAOYSA-N tert-butyl 4-(3-formyl-4-hydroxyphenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(O)C(C=O)=C1 HURFXWYAABUPFZ-UHFFFAOYSA-N 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- SHCWQWRTKPNTEM-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1Cl SHCWQWRTKPNTEM-UHFFFAOYSA-N 0.000 description 5
- PILLGAYDFOMSTJ-UHFFFAOYSA-N 2-hydroxy-4-piperazin-1-ylbenzaldehyde Chemical compound C1=C(C=O)C(O)=CC(N2CCNCC2)=C1 PILLGAYDFOMSTJ-UHFFFAOYSA-N 0.000 description 5
- JAARXSVCUDUSTR-UHFFFAOYSA-N 3-[3-[4-(aminomethyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound C1=CC(CN)=CC=C1N1C2=NC(C=3C=CC=CC=3)=CC=C2N=C1C1=CC=CN=C1N JAARXSVCUDUSTR-UHFFFAOYSA-N 0.000 description 5
- RGDKQPDDLFBPMH-UHFFFAOYSA-N 3-[3-[4-(aminomethyl)phenyl]imidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound C1=CC(CN)=CC=C1N1C2=NC=CC=C2N=C1C1=CC=CN=C1N RGDKQPDDLFBPMH-UHFFFAOYSA-N 0.000 description 5
- 230000007730 Akt signaling Effects 0.000 description 5
- 229910015845 BBr3 Inorganic materials 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 4
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 4
- 229910010084 LiAlH4 Inorganic materials 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 4
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- FLWVIVHZDIYIFM-UHFFFAOYSA-N benzyl 4-(cyclopropylamino)piperidine-1-carboxylate Chemical compound C1CC(NC2CC2)CCN1C(=O)OCC1=CC=CC=C1 FLWVIVHZDIYIFM-UHFFFAOYSA-N 0.000 description 4
- IZGQGPSUCXFAMC-UHFFFAOYSA-N benzyl 4-[cyclopropyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC=2C=CC=CC=2)CCC1N(C(=O)OC(C)(C)C)C1CC1 IZGQGPSUCXFAMC-UHFFFAOYSA-N 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 230000007257 malfunction Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000003197 protein kinase B inhibitor Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 125000005017 substituted alkenyl group Chemical group 0.000 description 4
- 125000004426 substituted alkynyl group Chemical group 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- NCJXULDVUJTZAP-UHFFFAOYSA-N tert-butyl N-[[4-[(3-nitropyridin-2-yl)amino]phenyl]methyl]carbamate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1NC1=NC=CC=C1[N+]([O-])=O NCJXULDVUJTZAP-UHFFFAOYSA-N 0.000 description 4
- BBTYZGAMQZKFQN-UHFFFAOYSA-N tert-butyl N-[[4-[2-(2-aminopyridin-3-yl)-5-chloroimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]carbamate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1N1C2=NC(Cl)=CC=C2N=C1C1=CC=CN=C1N BBTYZGAMQZKFQN-UHFFFAOYSA-N 0.000 description 4
- COSXQRGJLFEFGJ-VIFPVBQESA-N tert-butyl n-[(1s)-1-(4-aminophenyl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](C)C1=CC=C(N)C=C1 COSXQRGJLFEFGJ-VIFPVBQESA-N 0.000 description 4
- XMIOXPAPQXOJLH-VIFPVBQESA-N tert-butyl n-[(1s)-1-(4-nitrophenyl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](C)C1=CC=C([N+]([O-])=O)C=C1 XMIOXPAPQXOJLH-VIFPVBQESA-N 0.000 description 4
- UCTJMPXDBWLVDR-UHFFFAOYSA-N tert-butyl n-[[4-[(6-chloro-3-nitropyridin-2-yl)amino]phenyl]methyl]carbamate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1NC1=NC(Cl)=CC=C1[N+]([O-])=O UCTJMPXDBWLVDR-UHFFFAOYSA-N 0.000 description 4
- HGVUGEIGWHRYKR-UHFFFAOYSA-N tert-butyl n-[[4-[2-(2-aminopyridin-3-yl)-5-phenylimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]carbamate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1N1C2=NC(C=3C=CC=CC=3)=CC=C2N=C1C1=CC=CN=C1N HGVUGEIGWHRYKR-UHFFFAOYSA-N 0.000 description 4
- UJDBIWOTZJFYQT-UHFFFAOYSA-N tert-butyl n-[[4-[2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]methyl]carbamate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1N1C2=NC=CC=C2N=C1C1=CC=CN=C1N UJDBIWOTZJFYQT-UHFFFAOYSA-N 0.000 description 4
- VJXUGXISVNWCCA-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-piperidin-4-ylcarbamate Chemical compound C1CNCCC1N(C(=O)OC(C)(C)C)C1CC1 VJXUGXISVNWCCA-UHFFFAOYSA-N 0.000 description 4
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000000464 thioxo group Chemical group S=* 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- YDWCUVPRTSFLFD-UHFFFAOYSA-N 4-bromo-3-methoxy-N-methylaniline Chemical compound CNC1=CC=C(Br)C(OC)=C1 YDWCUVPRTSFLFD-UHFFFAOYSA-N 0.000 description 3
- MKKSTJKBKNCMRV-UHFFFAOYSA-N 5-bromo-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(Br)C=C1C=O MKKSTJKBKNCMRV-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000038030 PI3Ks Human genes 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- QTBZVPJKPNHRST-UHFFFAOYSA-N [4-[(3-nitropyridin-2-yl)amino]phenyl]methanol Chemical compound C1=CC(CO)=CC=C1NC1=NC=CC=C1[N+]([O-])=O QTBZVPJKPNHRST-UHFFFAOYSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000004808 supercritical fluid chromatography Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- YMOBOZKCFLAEHN-UHFFFAOYSA-N tert-butyl 4-(3-fluoro-4-formyl-5-hydroxyphenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC(O)=C(C=O)C(F)=C1 YMOBOZKCFLAEHN-UHFFFAOYSA-N 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 2
- PIBPHOFXQUUPTM-UHFFFAOYSA-N 3-bromo-2-methoxybenzoic acid Chemical compound COC1=C(Br)C=CC=C1C(O)=O PIBPHOFXQUUPTM-UHFFFAOYSA-N 0.000 description 2
- RUTNWXBHRAIQSP-UHFFFAOYSA-N 4-bromo-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1Br RUTNWXBHRAIQSP-UHFFFAOYSA-N 0.000 description 2
- GBJJCODOZGPTBC-UHFFFAOYSA-N 4-fluoro-2-hydroxybenzaldehyde Chemical compound OC1=CC(F)=CC=C1C=O GBJJCODOZGPTBC-UHFFFAOYSA-N 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102100020944 Integrin-linked protein kinase Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 102000046941 Rapamycin-Insensitive Companion of mTOR Human genes 0.000 description 2
- 108700019586 Rapamycin-Insensitive Companion of mTOR Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 108010059517 integrin-linked kinase Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- ZCZVQJLBRKFTDC-UHFFFAOYSA-N tert-butyl 4-(4-formyl-3-hydroxyphenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(C=O)C(O)=C1 ZCZVQJLBRKFTDC-UHFFFAOYSA-N 0.000 description 2
- UXWQXBSQQHAGMG-UHFFFAOYSA-N tert-butyl n-[(4-aminophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(N)C=C1 UXWQXBSQQHAGMG-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 1
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006313 (C5-C8) alkyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- QWEWLLNSJDTOKH-UHFFFAOYSA-N 1,3-thiazole-2-carboxamide Chemical class NC(=O)C1=NC=CS1 QWEWLLNSJDTOKH-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- RSNQVABHABAKEZ-UHFFFAOYSA-N 2,3-diphenylquinoxaline Chemical class C1=CC=CC=C1C1=NC2=CC=CC=C2N=C1C1=CC=CC=C1 RSNQVABHABAKEZ-UHFFFAOYSA-N 0.000 description 1
- MIHBQNSVCKHGOA-UHFFFAOYSA-N 2,4-difluoro-6-hydroxybenzaldehyde Chemical compound OC1=CC(F)=CC(F)=C1C=O MIHBQNSVCKHGOA-UHFFFAOYSA-N 0.000 description 1
- DOSGEBYQRMBTGS-UHFFFAOYSA-N 2-(3,6-dihydro-2h-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCOCC1 DOSGEBYQRMBTGS-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- YTAASTFSTXYEIX-UHFFFAOYSA-N 2-amino-5-bromo-4-methoxybenzoic acid Chemical compound COC1=CC(N)=C(C(O)=O)C=C1Br YTAASTFSTXYEIX-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- GCFJMEJVRHBPJI-UHFFFAOYSA-N 2-bromo-3-methoxyphenol Chemical compound COC1=CC=CC(O)=C1Br GCFJMEJVRHBPJI-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZLODWCIXZJMLJL-UHFFFAOYSA-N 3-bromo-2-methoxyaniline Chemical compound COC1=C(N)C=CC=C1Br ZLODWCIXZJMLJL-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- RAEVOBPXEHVUFY-LURJTMIESA-N 4187-53-5 Chemical compound C[C@H](N)C1=CC=C([N+]([O-])=O)C=C1 RAEVOBPXEHVUFY-LURJTMIESA-N 0.000 description 1
- WWQQPSDIIVXFOX-UHFFFAOYSA-N 5-bromo-2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC(Br)=CN=C1Cl WWQQPSDIIVXFOX-UHFFFAOYSA-N 0.000 description 1
- FDUBQNUDZOGOFE-UHFFFAOYSA-N 5-fluoro-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(F)C=C1C=O FDUBQNUDZOGOFE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241001251200 Agelas Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 1
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 101100340196 Mus musculus Il27ra gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 102100027069 Odontogenic ameloblast-associated protein Human genes 0.000 description 1
- 101710091533 Odontogenic ameloblast-associated protein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 102000010995 Pleckstrin homology domains Human genes 0.000 description 1
- 108050001185 Pleckstrin homology domains Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000007531 Proteus syndrome Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101001117144 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) [Pyruvate dehydrogenase (acetyl-transferring)] kinase 1, mitochondrial Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- IUHFWCGCSVTMPG-UHFFFAOYSA-N [C].[C] Chemical class [C].[C] IUHFWCGCSVTMPG-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 150000001537 azepanes Chemical class 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000005875 benzo[b][1,4]dioxepinyl group Chemical group 0.000 description 1
- 125000005876 benzo[b][1,4]oxazinyl group Chemical group 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- VZOVOHRDLOYBJX-UHFFFAOYSA-N benzyl 4-oxopiperidine-1-carboxylate Chemical compound C1CC(=O)CCN1C(=O)OCC1=CC=CC=C1 VZOVOHRDLOYBJX-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 description 1
- MXQOYLRVSVOCQT-UHFFFAOYSA-N bis(tri-t-butylphosphine)palladium (0) Substances [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ILAJWURWJKXJPW-UHFFFAOYSA-N butanedioic acid;octanedioic acid Chemical class OC(=O)CCC(O)=O.OC(=O)CCCCCCC(O)=O ILAJWURWJKXJPW-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical group C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 208000002409 gliosarcoma Diseases 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- RUMVKBSXRDGBGO-UHFFFAOYSA-N indole-3-carbinol Chemical class C1=CC=C[C]2C(CO)=CN=C21 RUMVKBSXRDGBGO-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000004272 isoquinoline-5-sulfonamides Chemical class 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- NOUUUQMKVOUUNR-UHFFFAOYSA-N n,n'-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1NCCNC1=CC=CC=C1 NOUUUQMKVOUUNR-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Chemical group C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000008048 phenylpyrazoles Chemical class 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000029964 regulation of glucose metabolic process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- KVOUHLVOTMOJBS-UHFFFAOYSA-N tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC11CNC1 KVOUHLVOTMOJBS-UHFFFAOYSA-N 0.000 description 1
- NRADOPGBTAJXKB-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CNC1 NRADOPGBTAJXKB-UHFFFAOYSA-N 0.000 description 1
- HPPARSNAMZJAPZ-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.4]nonane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC11CNCC1 HPPARSNAMZJAPZ-UHFFFAOYSA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- CZYUGTLMFHDODF-UHFFFAOYSA-N tert-butyl 4-(methylamino)piperidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)CC1 CZYUGTLMFHDODF-UHFFFAOYSA-N 0.000 description 1
- ZTYRRWNDQSVOCL-UHFFFAOYSA-N tert-butyl 4-[(4-aminophenyl)methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC=C(N)C=C1 ZTYRRWNDQSVOCL-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- WDXXUJZDWWVICV-UHFFFAOYSA-N tert-butyl N-[1-[(4-aminophenyl)methyl]piperidin-4-yl]carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1CC1=CC=C(N)C=C1 WDXXUJZDWWVICV-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- MIYUNZAWHSSBPU-UHFFFAOYSA-N tert-butyl n-(azepan-4-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCNCC1 MIYUNZAWHSSBPU-UHFFFAOYSA-N 0.000 description 1
- JGRCDKUNLLBMTE-UHFFFAOYSA-N tert-butyl n-ethyl-n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)N(CC)C1CCNCC1 JGRCDKUNLLBMTE-UHFFFAOYSA-N 0.000 description 1
- DJJOYDXRUBOZON-UHFFFAOYSA-N tert-butyl n-methyl-n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C1CCNCC1 DJJOYDXRUBOZON-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical class NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- INQOMBQAUSQDDS-FIBGUPNXSA-N trideuterio(iodo)methane Chemical compound [2H]C([2H])([2H])I INQOMBQAUSQDDS-FIBGUPNXSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- AKT1 MODULATORS CROSS REFERENCE [0001] This application claims the benefit of U.S. Provisional Application No.63/376,252 filed September 19, 2022, which is incorporated herein by reference in its entirety.
- BACKGROUND [0002] AKT is a protein kinase and mediates cell survival and proliferation by inhibiting pathways which promotes apoptosis. AKT signaling cascade dysfunction is observed in several cancer types and may be associated with tumor aggressiveness. Additionally, malfunction of AKT typically lead to enhanced proliferation, growth, survival, and resistance to apoptosis. Pharmaceutical agents with the ability to modulate AKT1 activity would be useful in the treatment of disease, such as cancer.
- One embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein: Z 1 is N, C-H, or C-R 3 ; Z 2 is N, C-H, or C-R 4 ; Ar is selected from X 1 is N or C-R 7 ; X 2 is N or C-R 7 ; X 3 is N or C-R 7 ; R 1 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, optionally substituted carbocyclyl, or optionally substituted heteroaryl; R 3 is selected from optionally substituted C1-C6
- One embodiment provides a compound having the structure of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof: wherein: Z 1 is N, C-H, or C-R 3 ; Z 2 is N, C-H, or C-R 4 ; Ar is selected from X 1 is N or C-R 7 ; X 2 is N or C-R 7 ; X 3 is N or C-R 7 ; R 1 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 3 is selected from optionally substituted C1-C6 alkyl, or optionally substituted aryl; R 4 is selected from optionally substituted C1-C6 alkyl, or optionally substituted aryl; R 5 and R 6 are each independently hydrogen, deuterium, halogen, -
- R 8 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C7 cycloalkyl, or optionally substituted heterocyclyl; m is 0, 1, or 2; n is 1, 2, or 3; and q is 0 or 1.
- One embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt or solvate thereof: wherein: Z 1 is N, C-H, or C-R 3 ; Z 2 is N, C-H, or C-R 4 ; Ar is selected from X 1 is N or C-R 5 ; X 2 is N or C-R 5 ; X 3 is N or C-R 5 ; R 1 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 3 is selected from optionally substituted C1-C6 alkyl, or optionally substituted aryl; R 4 is selected from optionally substituted C1-C6 alkyl, or optionally substituted aryl; and each R 5 is independently selected from hydrogen, halogen, -OH, -
- One embodiment provides a pharmaceutical composition comprising a compound of Formula (I) or (II), or pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.
- One embodiment provides a method of treating a disease or disorder in a patient in need thereof comprising administering to the patient a compound of Formula (I) or (II), or pharmaceutically acceptable salt or solvate thereof.
- Another embodiment provides the method wherein the disease or disorder is cancer.
- Alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to fifteen carbon atoms (e.g., C 1 -C 15 alkyl).
- an alkyl comprises one to thirteen carbon atoms (e.g., C1-C13 alkyl).
- an alkyl comprises one to eight carbon atoms (e.g., C1-C8 alkyl).
- an alkyl comprises one to five carbon atoms (e.g., C 1 -C 5 alkyl).
- an alkyl comprises one to four carbon atoms (e.g., C 1 - C4 alkyl). In other embodiments, an alkyl comprises one to three carbon atoms (e.g., C1-C3 alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (e.g., C1-C2 alkyl). In other embodiments, an alkyl comprises one carbon atom (e.g., C 1 alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (e.g., C5-C15 alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (e.g., C5-C8 alkyl).
- an alkyl comprises two to five carbon atoms (e.g., C 2 -C 5 alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (e.g., C 3 -C 5 alkyl).
- the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (iso-propyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl).
- alkyl is attached to the rest of the molecule by a single bond.
- an alkyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a ) 2 , -C(O)R a , -C(O)OR a , -C(O)N(R a ) 2 , - N(R a )C(O)OR a , -OC(O)-N(R a )2, -N(R a )C(O)R a , -N(R a )S(O)tR a (where t is 1 or 2), -S(O)tOR a (where t is 1 or 2), -S
- an optionally substituted alkyl is a haloalkyl. In other embodiments, an optionally substituted alkyl is a fluoroalkyl. In other embodiments, an optionally substituted alkyl is a -CF 3 group.
- Alkoxy refers to a radical bonded through an oxygen atom of the formula –O-alkyl, where alkyl is an alkyl chain as defined above.
- Alkenyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms.
- an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to four carbon atoms.
- the alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like.
- an alkenyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a ) 2 , -C(O)R a , -C(O)OR a , -C(O)N(R a ) 2 , - N(R a )C(O)OR a , -OC(O)-N(R a )2, -N(R a )C(O)R a , -N(R a )S(O)tR a (where t is 1 or 2), -S(O)tOR a (where t is 1 or 2), -S(O)tOR a (where t is 1 or 2), -S
- Alkynyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, having from two to twelve carbon atoms.
- an alkynyl comprises two to eight carbon atoms.
- an alkynyl comprises two to six carbon atoms.
- an alkynyl comprises two to four carbon atoms.
- the alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
- an alkynyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , - C(O)N(R a )2, -N(R a )C(O)OR a , -OC(O)-N(R a )2, -N(R a )C(O)R a , -N(R a )S(O)tR a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is
- Alkylene or "alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation, and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like.
- the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
- the points of attachment of the alkylene chain to the rest of the molecule and to the radical group are through one carbon in the alkylene chain or through any two carbons within the chain.
- an alkylene comprises one to eight carbon atoms (e.g., C 1 -C 8 alkylene). In other embodiments, an alkylene comprises one to five carbon atoms (e.g., C1-C5 alkylene). In other embodiments, an alkylene comprises one to four carbon atoms (e.g., C 1 -C 4 alkylene). In other embodiments, an alkylene comprises one to three carbon atoms (e.g., C 1 -C 3 alkylene). In other embodiments, an alkylene comprises one to two carbon atoms (e.g., C1-C2 alkylene). In other embodiments, an alkylene comprises one carbon atom (e.g., C1 alkylene).
- an alkylene comprises five to eight carbon atoms (e.g., C5-C8 alkylene). In other embodiments, an alkylene comprises two to five carbon atoms (e.g., C 2 -C 5 alkylene). In other embodiments, an alkylene comprises three to five carbon atoms (e.g., C 3 -C 5 alkylene).
- an alkylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a ) 2 , -C(O)R a , -C(O)OR a , - C(O)N(R a )2, -N(R a )C(O)OR a , -OC(O)-N(R a )2, -N(R a )C(O)R a , -N(R a )S(O)tR a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is
- alkenylene or "alkenylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms.
- the alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
- an alkenylene comprises two to eight carbon atoms (e.g., C 2 -C 8 alkenylene).
- an alkenylene comprises two to five carbon atoms (e.g., C2-C5 alkenylene).
- an alkenylene comprises two to four carbon atoms (e.g., C2-C4 alkenylene). In other embodiments, an alkenylene comprises two to three carbon atoms (e.g., C 2 -C 3 alkenylene). In other embodiments, an alkenylene comprises two carbon atoms (e.g., C 2 alkenylene). In other embodiments, an alkenylene comprises five to eight carbon atoms (e.g., C5-C8 alkenylene). In other embodiments, an alkenylene comprises three to five carbon atoms (e.g., C 3 -C 5 alkenylene).
- an alkenylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a ) 2 , -C(O)R a , -C(O)OR a , -C(O)N(R a ) 2 , - N(R a )C(O)OR a , -OC(O)-N(R a ) 2 , -N(R a )C(O)R a , -N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O)tR a
- Alkynylene or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon triple bond, and having from two to twelve carbon atoms.
- the alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
- an alkynylene comprises two to eight carbon atoms (e.g., C2-C8 alkynylene).
- an alkynylene comprises two to five carbon atoms (e.g., C 2 -C 5 alkynylene).
- an alkynylene comprises two to four carbon atoms (e.g., C 2 -C 4 alkynylene). In other embodiments, an alkynylene comprises two to three carbon atoms (e.g., C2-C3 alkynylene). In other embodiments, an alkynylene comprises two carbon atoms (e.g., C2 alkynylene). In other embodiments, an alkynylene comprises five to eight carbon atoms (e.g., C 5 -C 8 alkynylene). In other embodiments, an alkynylene comprises three to five carbon atoms (e.g., C3-C5 alkynylene).
- an alkynylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , - C(O)N(R a )2, -N(R a )C(O)OR a , -OC(O)-N(R a )2, -N(R a )C(O)R a , -N(R a )S(O)tR a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is
- Aryl refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom.
- the aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from five to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) –electron system in accordance with the Hückel theory.
- the ring system from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene.
- aryl or the prefix “ar-” (such as in “aralkyl”) is meant to include aryl radicals optionally substituted by one or more substituents independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, cyano, nitro, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b - OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a )2, -R b -O-R c -C(O)N(R a )2, -
- Aralkyl refers to a radical of the formula -R c -aryl where R c is an alkylene chain as defined above, for example, methylene, ethylene, and the like.
- the alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain.
- the aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
- “Aralkenyl” refers to a radical of the formula –R d -aryl where R d is an alkenylene chain as defined above.
- the aryl part of the aralkenyl radical is optionally substituted as described above for an aryl group.
- alkenylene chain part of the aralkenyl radical is optionally substituted as defined above for an alkenylene group.
- "Aralkynyl” refers to a radical of the formula -R e -aryl, where R e is an alkynylene chain as defined above.
- the aryl part of the aralkynyl radical is optionally substituted as described above for an aryl group.
- the alkynylene chain part of the aralkynyl radical is optionally substituted as defined above for an alkynylene chain.
- Alkoxy refers to a radical bonded through an oxygen atom of the formula - O-R c -aryl where R c is an alkylene chain as defined above, for example, methylene, ethylene, and the like.
- the alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain.
- the aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
- Carbocyclyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which includes fused or bridged ring systems, having from three to fifteen carbon atoms.
- a carbocyclyl comprises three to ten carbon atoms. In other embodiments, a carbocyclyl comprises five to seven carbon atoms. The carbocyclyl is attached to the rest of the molecule by a single bond. Carbocyclyl is saturated (i.e., containing single C-C bonds only) or unsaturated (i.e., containing one or more double bonds or triple bonds).
- a fully saturated carbocyclyl radical is also referred to as "cycloalkyl.”
- monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- An unsaturated carbocyclyl is also referred to as "cycloalkenyl.”
- Examples of monocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
- Polycyclic carbocyclyl radicals include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
- carbocyclyl is meant to include carbocyclyl radicals that are optionally substituted by one or more substituents independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, oxo, thioxo, cyano, nitro, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a ) 2 , -R b - N(R a ) 2 , -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a ) 2 , -R b -O-R c -C(O)N(R b -OR a , -R b
- Carbocyclylalkyl refers to a radical of the formula –R c -carbocyclyl where R c is an alkylene chain as defined above. The alkylene chain and the carbocyclyl radical is optionally substituted as defined above.
- Carbocyclylalkynyl refers to a radical of the formula –R c -carbocyclyl where R c is an alkynylene chain as defined above. The alkynylene chain and the carbocyclyl radical is optionally substituted as defined above.
- Carbocyclylalkoxy refers to a radical bonded through an oxygen atom of the formula – O-R c -carbocyclyl where R c is an alkylene chain as defined above. The alkylene chain and the carbocyclyl radical is optionally substituted as defined above.
- Halo or “halogen” refers to bromo, chloro, fluoro or iodo substituents.
- Fluoroalkyl refers to an alkyl radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like.
- the alkyl part of the fluoroalkyl radical is optionally substituted as defined above for an alkyl group.
- Heterocyclyl refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur.
- the heterocyclyl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which optionally includes fused or bridged ring systems.
- the heteroatoms in the heterocyclyl radical are optionally oxidized.
- One or more nitrogen atoms, if present, are optionally quaternized.
- the heterocyclyl radical is partially or fully saturated.
- the heterocyclyl is attached to the rest of the molecule through any atom of the ring(s).
- heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thio
- heterocyclyl is meant to include heterocyclyl radicals as defined above that are optionally substituted by one or more substituents selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, - R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R a , -R b - C(O)OR a , -R b -C(O)N(R a ) 2 , -R b -O-R c -C(O)OR a , -R b -C(
- N-heterocyclyl or “N-attached heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical.
- An N-heterocyclyl radical is optionally substituted as described above for heterocyclyl radicals. Examples of such N-heterocyclyl radicals include, but are not limited to, 1-morpholinyl, 1- piperidinyl, 1-piperazinyl, 1-pyrrolidinyl, pyrazolidinyl, and imidazolidinyl.
- C-heterocyclyl or “C-attached heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one heteroatom and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a carbon atom in the heterocyclyl radical.
- a C-heterocyclyl radical is optionally substituted as described above for heterocyclyl radicals. Examples of such C-heterocyclyl radicals include, but are not limited to, 2-morpholinyl, 2- or 3- or 4-piperidinyl, 2-piperazinyl, 2- or 3-pyrrolidinyl, and the like.
- Heterocyclylalkyl refers to a radical of the formula –R c -heterocyclyl where R c is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom.
- the alkylene chain of the heterocyclylalkyl radical is optionally substituted as defined above for an alkylene chain.
- the heterocyclyl part of the heterocyclylalkyl radical is optionally substituted as defined above for a heterocyclyl group.
- Heterocyclylalkoxy refers to a radical bonded through an oxygen atom of the formula –O-R c -heterocyclyl where R c is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom.
- the alkylene chain of the heterocyclylalkoxy radical is optionally substituted as defined above for an alkylene chain.
- the heterocyclyl part of the heterocyclylalkoxy radical is optionally substituted as defined above for a heterocyclyl group.
- Heteroaryl refers to a radical derived from a 3- to 18-membered aromatic ring radical that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen, and sulfur.
- the heteroaryl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) –electron system in accordance with the Hückel theory.
- Heteroaryl includes fused or bridged ring systems.
- the heteroatom(s) in the heteroaryl radical is optionally oxidized.
- heteroaryl is attached to the rest of the molecule through any atom of the ring(s).
- heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothienyl (benzothion
- heteroaryl is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from optionally substituted alkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclylalkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, optionally substituted fluoroalkyl, optionally substituted haloalkenyl, optionally substituted haloalkynyl, oxo, thioxo, cyano, nitro, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , - R b -OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R
- N-heteroaryl refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical.
- An N-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
- C-heteroaryl refers to a heteroaryl radical as defined above and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a carbon atom in the heteroaryl radical.
- a C-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
- Heteroarylalkyl refers to a radical of the formula –R c -heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
- the alkylene chain of the heteroarylalkyl radical is optionally substituted as defined above for an alkylene chain.
- the heteroaryl part of the heteroarylalkyl radical is optionally substituted as defined above for a heteroaryl group.
- Heteroarylalkoxy refers to a radical bonded through an oxygen atom of the formula – O-R c -heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
- the alkylene chain of the heteroarylalkoxy radical is optionally substituted as defined above for an alkylene chain.
- the heteroaryl part of the heteroarylalkoxy radical is optionally substituted as defined above for a heteroaryl group.
- the compounds disclosed herein in some embodiments, contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that are defined, in terms of absolute stereochemistry, as (R)- or (S)-. Unless stated otherwise, it is intended that all stereoisomeric forms of the compounds disclosed herein are contemplated by this disclosure. When the compounds described herein contain alkene double bonds, and unless specified otherwise, it is intended that this disclosure includes both E and Z geometric isomers (e.g., cis or trans.) Likewise, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included.
- geometric isomer refers to E or Z geometric isomers (e.g., cis or trans) of an alkene double bond.
- positional isomer refers to structural isomers around a central ring, such as ortho-, meta-, and para- isomers around a benzene ring.
- carboxylic acid bioisostere refers to a functional group or moiety that exhibits similar physical, biological and/or chemical properties as a carboxylic acid moiety. Examples of carboxylic acid bioisosteres include, but are not limited to, .
- a "tautomer” refers to a molecule wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible.
- the compounds disclosed herein are used in different enriched isotopic forms, e.g., enriched in the content of 2 H, 3 H, 11 C, 13 C and/or 14 C.
- the compound is deuterated in at least one position.
- deuterated forms can be made by the procedure described in U.S. Patent Nos.5,846,514 and 6,334,997.
- deuteration can improve the metabolic stability and or efficacy, thus increasing the duration of action of drugs.
- structures depicted herein are intended to include compounds which differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon are within the scope of the present disclosure.
- the compounds of the present disclosure optionally contain unnatural proportions of atomic isotopes at one or more atoms that constitute such compounds.
- the compounds may be labeled with isotopes, such as for example, deuterium ( 2 H), tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C).
- deuterium substituted compounds are synthesized using various methods such as described in: Dean, Dennis C.; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [Curr., Pharm. Des., 2000; 6(10)] 2000, 110 pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal.
- Deuterated starting materials are readily available and are subjected to the synthetic methods described herein to provide for the synthesis of deuterium-containing compounds. Large numbers of deuterium-containing reagents and building blocks are available commercially from chemical vendors, such as Aldrich Chemical Co.
- Deuterium-transfer reagents suitable for use in nucleophilic substitution reactions such as iodomethane-d 3 (CD 3 I) are readily available and may be employed to transfer a deuterium- substituted carbon atom under nucleophilic substitution reaction conditions to the reaction substrate.
- CD3I is illustrated, by way of example only, in the reaction schemes below.
- Deuterium-transfer reagents such as lithium aluminum deuteride (LiAlD4) are employed to transfer deuterium under reducing conditions to the reaction substrate.
- LiAlD 4 is illustrated, by way of example only, in the reaction schemes below.
- Deuterium gas and palladium catalyst are employed to reduce unsaturated carbon-carbon linkages and to perform a reductive substitution of aryl carbon-halogen bonds as illustrated, by way of example only, in the reaction schemes below.
- the compounds disclosed herein contain one deuterium atom. In another embodiment, the compounds disclosed herein contain two deuterium atoms. In another embodiment, the compounds disclosed herein contain three deuterium atoms.
- the compounds disclosed herein contain four deuterium atoms. In another embodiment, the compounds disclosed herein contain five deuterium atoms. In another embodiment, the compounds disclosed herein contain six deuterium atoms. In another embodiment, the compounds disclosed herein contain more than six deuterium atoms. In another embodiment, the compound disclosed herein is fully substituted with deuterium atoms and contains no non-exchangeable 1 H hydrogen atoms. In one embodiment, the level of deuterium incorporation is determined by synthetic methods in which a deuterated synthetic building block is used as a starting material. [0060] "Pharmaceutically acceptable salt” includes both acid and base addition salts.
- a pharmaceutically acceptable salt of any one of the AKT1 inhibitory compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms.
- Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
- “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like.
- salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and. aromatic sulfonic acids, etc.
- acetic acid trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
- Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like.
- salts of amino acids such as arginates, gluconates, and galacturonates
- Acid addition salts of basic compounds are, in some embodiments, prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt according to methods and techniques with which a skilled artisan is familiar.
- “Pharmaceutically acceptable base addition salt” refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid.
- Pharmaceutically acceptable base addition salts are, in some embodiments, formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
- Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N- dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
- solvates refers to a composition of matter that is the solvent addition form.
- solvates contain either stoichiometric or non- stoichiometric amounts of a solvent, and are formed during the process of making with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein are conveniently prepared or formed during the processes described herein. The compounds provided herein exist in either unsolvated or solvated forms.
- the term “subject” or “patient” encompasses mammals.
- mammals include, but are not limited to, any member of the mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
- the mammal is a human.
- “treatment” or “treating,” or “palliating” or “ameliorating” are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit.
- compositions are, in some embodiments, administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.
- AKT1 Protein and Function [0066] AKT, also known as protein kinase B (PKB), is a serine/threonine protein kinase with three isoforms, AKT1, AKT2, and AKT3. While the isoforms are encoded by different genes, they are highly homologous at the protein level and share a conserved domain structure comprising an N-terminal pleckstrin homology (PH) domain, a kinase domain, and a C-terminal regulatory domain comprising a hydrophobic moiety, which includes the regulatory serine residue (Nitulescu, G. M. et al., Int J Oncol., 2018; 53(6): 2319-2331).
- PH N-terminal pleckstrin homology
- AKT proteins play a crucial role in major cellular functions including cell cycle progression, cell size, regulation of glucose metabolism, transcription, protein synthesis, genome stability, and neovascularization. AKT proteins can block apoptosis by inactivation of pro- apoptotic proteins, and mediate cellular growth factors, promoting cell survival. AKT is a major nucleus of a cell. [0068] AKT1 is ubiquitously expressed, whereas AKT2 is primarily expressed in insulin- responsive tissues, and AKT3 is primarily expressed in brain and testes.
- a shared phosphorylation site of AKT in the catalytic domain corresponds to a threonine residue; specifically, Thr308 in AKT1, Thr309 in AKT2, and Thr305 in AKT3.
- a shared phosphorylation site in the C-terminus of the protein c is a serine residue; specifically, Ser473 in AKT1, Ser474 in AKT2, and Ser472 in AKT3.
- PI3K phosphoinositide-3-kinase
- the AKT cascade can be activated by RTKs and G-protein-compound receptors (GPCRs), along with other signals including integrins, B cell receptors, T cell receptors, and cytokine receptors.
- GPCRs G-protein-compound receptors
- AKT1 Mechanism AKT is activated by a second phosphorylation at the regulatory serine residue, Ser473.
- Known phosphorylating agents of AKT at Ser473 include, but are not limited to PDK-1, integrin-linked kinase (ILK), members of the PI3K-related kinase (PIKK) family, and mammalian target of rapamycin (mTOR) (Nitulescu, G. M.
- mTOR is a key component in the AKT signaling pathway, which is a downstream member of AKT and important regulator for cell metabolism and growth. mTOR is also an activator which can directly phosphorylate AKT’s regulatory serine residue, Ser473. mTOR forms a complex with rapamycin-insensitive companion of mTOR (RICTOR) (and other proteins) to form mTOR complex 2 (mTORC2), which can directly phosphorylate AKT Ser473.
- RICTOR rapamycin-insensitive companion of mTOR
- mTORC2 mTOR complex 2
- AKT can affect cell survival and growth because it can influence the tuberous sclerosis complex (TSC) 1/2 along the mTORC signaling pathway and inhibit pro-apoptotic proteins or signals.
- AKT is known as a survival kinase and mediates cell survival and proliferation by inhibiting pathways including, but not limited to Bcl2 and MDM2, which promotes apoptosis.
- Bcl2 and MDM2 promotes apoptosis.
- Malfunctions of AKT typically lead to enhanced proliferation, growth, survival, and resistance to apoptosis (Alwhaibi, A. et al., Pharmacol Res., 2019, 145: 104270).
- AKT1 has been found to be involved in invasion and migration of cancerous cells (Alwhaibi, A. et al., Pharmacol Res., 2019, 145: 104270). researchers found that silencing the AKT1 isoform can abrogate specific types of cancer cell migration. However, there have been other studies which have demonstrated that activated AKT1 resulted in less metastatic propensity for lung metastatic lesion cells and breast cancer cells.
- AKT1 has also been identified as a key protein involved in angiogenesis, lung cancer, and tumorigenesis.
- overexpression of AKT has been correlated to resistance to chemotherapeutic agents such as cisplatin, methotrexate, and paclitaxel.
- chemotherapeutic agents such as cisplatin, methotrexate, and paclitaxel.
- chemotherapeutic agents such as cisplatin, methotrexate, and paclitaxel.
- the AKT1 gene mutation E17K can affect cell growth, proliferation, survival, and migration of breast cancer cells, colorectal cancer cells, and ovarian cancer cells (Chen, Y. et al., Front Cell Dev Biol., 2020; 8: 573599).
- AKT1 to Phosphatidylinositol-3,4,5-triphosphate (PIP3) lipid ligand, which accelerates transfer of AKT from the cytoplasm to the cell membrane through formation of hydrogen bonds. Transfer of AKT into the cell membrane allows it to be further phosphorylated. Once fully activated, AKT can return to the cytoplasm, or go to the nucleus or other intracellular sites, and phosphorylate other substrate proteins to regulate cell function.
- PIP3 Phosphatidylinositol-3,4,5-triphosphate
- a major pathway that activates PI3K-AKT signaling pathway is somatic cell mutations, with the E17K mutation being the highest frequency of AKT1 mutations. It is nearly exclusively present in AKT1.
- the AKT1(E17K) is a recurrent somatic cell mutation predominantly in breast cancer, ovarian cancer, meningioma, and Proteus syndrome.
- AKT1(E17K) mutations mediate the PI3K-AKT signaling cascade by expanding PIP lipid specificity, which causes conformational changes. This also enhances subcellular localization to accelerate localization of the PH structural domain to the plasma membrane.
- the E17K mutation increases PIP3 binding specificity by 7-fold and phosphatidylinositol-(4,5)- bisphosphate (PIP2) by 100-fold.
- PIP2 phosphatidylinositol-(4,5)- bisphosphate
- the AKT1(E17K) mutation also causes rapid conformational changes in the AKT1 PH structural domain. The conformational changes to this domain result in a 4.5-fold increase in its membrane localization, which can result in excessive phosphorylation.
- the AKT1(E17K) mutation can also result in enhanced subcellular localization by increasing the transient expression. [0080] Given the conformational and signaling effects of the AKT1(E17K) mutation, this target may be useful for targeted treatment of cancers.
- Prior Art AKT1 Inhibitors [0081] Most AKT inhibitors targeting the ATP binding site are non-selective against the three isoforms, as well as having poor to no selectivity against other structurally similar kinases. Thus, there remains a need to develop new and novel AKT inhibitors.
- ATP targeting inhibitors are classified as aminofurazans, azepane derivatives, isoquinoline-5-sulfonamides, phenylpyrazole derivatives, thiophene carboxamide derivatives, and thiazole carboxamide derivatives.
- ATP non-competitive AKT inhibitors which are allosteric modulators which has greater specificity than the ATP targeting inhibitors.
- Many of these allosteric modulator inhibitors are classified as purine derivatives, thiourea derivatives, alkylphospholipids, sulfonamides, 2,3-diphenylquinoxaline analogs, and indole-3-carbinol derivatives.
- AKT1 inhibitory compound having the structure of Formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein: Z 1 is N, C-H, or C-R 3 ; Z 2 is N, C-H, or C-R 4 ; Ar is selected from X 1 is N or C-R 7 ; X 2 is N or C-R 7 ; X 3 is N or C-R 7 ; R 1 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, optionally substituted carbocyclyl, or optionally substituted heteroaryl; R 3 is selected from optionally substituted C1-C6 alkyl, or optionally substituted aryl; R 4 is selected from optionally
- One embodiment provides a compound having the structure of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof: wherein: Z 1 is N, C-H, or C-R 3 ; Z 2 is N, C-H, or C-R 4 ; Ar is selected from X 1 is N or C-R 7 ; X 2 is N or C-R 7 ; X 3 is N or C-R 7 ; R 1 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 3 is selected from optionally substituted C1-C6 alkyl, or optionally substituted aryl; R 4 is selected from optionally substituted C1-C6 alkyl, or optionally substituted aryl; R 5 and R 6 are each independently hydrogen, deuterium, halogen, -
- R 8 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C7 cycloalkyl, and optionally substituted heterocyclyl; m is 0, 1, or 2; n is 1, 2, or 3; and q is 0 or 1.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein Z 1 is N.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein Z 2 is C-H.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein Z 2 is C-R 4 .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted heteroaryl.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted heteroaryl is an optionally substituted pyridyl.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein R 2 is optionally substituted aryl.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted aryl is an optionally substituted phenyl.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein R 5 is hydrogen.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein R 6 is hydrogen.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 together form an oxo.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein R 6 is optionally substituted C1-C6 alkyl.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 join together to form a carbocycle or heterocycle.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein L is -N(R 8 )-.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein L is selected from: .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein L is selected from: .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein L is selected from: .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein L is selected from: .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein L is selected from: .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein L is selected from: .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein L is selected from: .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein R 8 is hydrogen or optionally substituted C1-C6 alkyl.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein q is 0.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein q is 1.
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein Ar is .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein Ar is .
- Another embodiment provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein X 1 , X 2 , and X 3 are C-H.
- One embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt or solvate thereof: wherein: Z 1 is N, C-H, or C-R 3 ; Z 2 is N, C-H, or C-R 4 ; Ar is selected from X 1 is N or C-R 5 ; X 2 is N or C-R 5 ; X 3 is N or C-R 5 ; R 1 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 3 is selected from optionally substituted C1-C6 alkyl, or optionally substituted aryl; R 4 is selected from optionally substituted C1-C6 alkyl, or optionally substituted aryl; and each R 5 is independently selected from hydrogen, halogen, -OH, -
- One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein Z 1 is N. [00112] One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein Z 2 is C-H. [00113] One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein Z 2 is C-R 4 . [00114] One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted heteroaryl.
- One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted heteroaryl is an optionally substituted pyridyl.
- One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein R 2 is optionally substituted aryl.
- One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted aryl is an optionally substituted phenyl.
- One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein .
- One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein Ar is .
- One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein .
- One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein Ar is .
- One embodiment provides a compound having the structure of Formula (II), or pharmaceutically acceptable salt or solvate thereof, wherein X 1 , X 2 , and X 3 are C-H.
- One embodiment provides an AKT1 inhibitory compound, or a pharmaceutically acceptable salt or solvate thereof, having a structure presented in Table 1. Table 1
- Another embodiment provides an AKT1 inhibitory compound, or a pharmaceutically acceptable salt or solvate thereof, having a structure presented in Table 2.
- Table 2
- compositions [00127]
- the AKT1 inhibitory compound described herein is administered as a pure chemical.
- the AKT1 inhibitory compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21 st Ed. Mack Pub. Co., Easton, PA (2005)).
- a pharmaceutical composition comprising at least one AKT1 inhibitory compound as described herein, or a stereoisomer, pharmaceutically acceptable salt, hydrate, or solvate thereof, together with one or more pharmaceutically acceptable carriers.
- the carrier(s) or excipient(s)
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
- One embodiment provides a method of preparing a pharmaceutical composition
- a method of preparing a pharmaceutical composition comprising mixing a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
- the AKT1 inhibitory compound as described by Formula (I), or a pharmaceutically acceptable salt or solvate thereof is substantially pure, in that it contains less than about 5%, or less than about 2%, or less than about 1%, or less than about 0.5%, or less than about 0.1%, of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof.
- One embodiment provides a method of preparing a pharmaceutical composition comprising mixing a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
- the AKT1 inhibitory compound as described by Formula (II), or a pharmaceutically acceptable salt or solvate thereof is substantially pure, in that it contains less than about 5%, or less than about 2%, or less than about 1%, or less than about 0.5%, or less than about 0.1%, of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.
- a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Table 1 or Table 2, or a pharmaceutically acceptable salt or solvate thereof.
- One embodiment provides a method of preparing a pharmaceutical composition
- a method of preparing a pharmaceutical composition comprising mixing a compound of Table 1 or Table 2, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
- the AKT1 inhibitory compound as described by Table 1 or Table 2, or a pharmaceutically acceptable salt or solvate thereof is substantially pure, in that it contains less than about 5%, or less than about 2%, or less than about 1%, or less than about 0.5%, or less than about 0.1%, of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.
- Suitable oral dosage forms include, for example, tablets, pills, sachets, or capsules of hard or soft gelatin, methylcellulose or of another suitable material easily dissolved in the digestive tract.
- suitable nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. (See, e.g., Remington: The Science and Practice of Pharmacy (Gennaro, 21 st Ed. Mack Pub. Co., Easton, PA (2005)).
- the AKT1 inhibitory compound as described by Formula (I) or Table 1 or Table 2, or pharmaceutically acceptable salt or solvate thereof is formulated for administration by injection.
- the injection formulation is an aqueous formulation.
- the injection formulation is a non-aqueous formulation.
- the injection formulation is an oil-based formulation, such as sesame oil, or the like.
- the dose of the composition comprising at least one AKT1 inhibitory compound as described herein differs depending upon the subject or patient's (e.g., human) condition. In some embodiments, such factors include general health status, age, and other factors.
- Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented).
- an appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration.
- an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity.
- Optimal doses are generally determined using experimental models and/or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient. [00142] Oral doses typically range from about 1.0 mg to about 1000 mg, one to four times, or more, per day.
- One embodiment provides a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.
- One embodiment provides a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of cancer or neoplastic disease.
- One embodiment provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient for use in a method of treatment of cancer or neoplastic disease.
- One embodiment provides a use of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of cancer or neoplastic disease.
- a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
- a method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
- One embodiment provides a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body. [00149] One embodiment provides a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of cancer or neoplastic disease. [00150] One embodiment provides a pharmaceutical composition comprising a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient for use in a method of treatment of cancer or neoplastic disease.
- One embodiment provides a use of a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of cancer or neoplastic disease.
- a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof.
- a method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
- One embodiment provides a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body. [00154] One embodiment provides a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of cancer or neoplastic disease. [00155] One embodiment provides a pharmaceutical composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient for use in a method of treatment of cancer or neoplastic disease.
- One embodiment provides a use of a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of cancer or neoplastic disease.
- a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof.
- a method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
- One embodiment provides a compound of Table 1 or Table 2, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body. [00159] One embodiment provides a compound of Table 1 or Table 2, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of cancer or neoplastic disease. [00160] One embodiment provides a pharmaceutical composition comprising a compound of Table 1 or Table 2, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient for use in a method of treatment of cancer or neoplastic disease.
- One embodiment provides a use of a compound of Table 1 or Table 2, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of cancer or neoplastic disease.
- a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Table 1 or Table 2, or a pharmaceutically acceptable salt or solvate thereof.
- a method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Table 1 or Table 2, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
- AKT1 enzyme comprising contacting the AKT1 enzyme with a compound of Formula (I), (II), or Table 1 or Table 2. Another embodiment provides the method of inhibiting a AKT1 enzyme, wherein the AKT1 enzyme is contacted in an in vivo setting. Another embodiment provides the method of inhibiting a AKT1 enzyme, wherein the AKT1 enzyme is contacted in an in vitro setting.
- Other embodiments and uses will be apparent to one skilled in the art in light of the present disclosures.
- Step 2 tert-Butyl 4-(2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3- yl)benzylcarbamate
- tert-butyl N-[[4-[(3-nitro-2-pyridyl)amino]phenyl]methyl]carbamate (10 g, 29.0 mmol) in MeOH (70 mL) and DMSO (140 mL) were added 2-aminopyridine-3- carbaldehyde (3.9 g, 31.9 mmol) and Na 2 S 2 O 4 (10.1 g, 58.1 mmol).
- Step 3 3-(3-(4-(Aminomethyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
- tert-butyl N-[[4-[2-(2-amino-3-pyridyl)imidazo[4,5-b]pyridin-3- yl]phenyl]methyl]carbamate 350 mg, 840 ⁇ mol
- 1,4-dioxane 3 mL
- the crude product was purified by prep-HPLC (Column: Phenomenex luna C18150 x 25 mm x 10 ⁇ m; Condition: water (HCl)-ACN; Begin B: 0; End B: 16; Gradient Time (min): 10; 100%B Hold Time (min): 2; Flow Rate (mL/min): 25) to give product (HCl salt).
- the product was diluted with aqueous NaHCO3 (10 mL) and extracted with DCM (10 mL x 3).
- Step 2 tert-Butyl N-[[4-[2-(2-amino-3-pyridyl)-5-chloro-imidazo[4,5-b]pyridin-3- yl]phenyl]methyl]carbamate
- tert-butyl N-[[4-[(6-chloro-3-nitro-2- pyridyl)amino]phenyl]methyl]carbamate 2.0 g, 5.3 mmol
- 2-aminopyridine-3-carbaldehyde 0.7 g, 5.8 mmol
- Na2S2O4 1.8 g, 10.6 mmol
- Step 3 tert-Butyl N-[[4-[2-(2-amino-3-pyridyl)-5-phenyl-imidazo[4,5-b]pyridin-3- yl]phenyl]methyl]carbamate
- tert-butyl N-[[4-[2-(2-amino-3-pyridyl)-5-chloro-imidazo[4,5- b]pyridin-3-yl]phenyl]methyl]carbamate 500 mg, 1.1 mmol
- phenylboronic acid 270 mg, 2.2 mmol,
- the mixture was degassed, purged with N 2 three times, and stirred at 80 °C for 16 hr under N2 atmosphere. After cooling to 20 °C, the reaction was diluted with EtOAc,( 10 mL). The mixture was filtered through celite and extracted with H 2 O (10 mL x 3). The combined organic layers were washed with brine (15 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue.
- Step 4 3-(3-(4-(Aminomethyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine [00182] To a solution of tert-butyl N-[[4-[2-(2-amino-3-pyridyl)-5-phenyl-imidazo[4,5- b]pyridin-3-yl]phenyl]methyl]carbamate (126 mg, 256 ⁇ mol) in HCl/1,4-dioxane (4 M, 1 mL). The mixture was stirred at 25 °C for 2 hr.
- the solvent was removed under reduced pressure to give a crude product (84 mg, yield: 84%).
- the crude product was purified by prep-HPLC (column: Welch Xtimate C18150 x 25mm x 5 ⁇ m; mobile phase: [water (HCl) - ACN]; B%: 5% - 35%, 8min) to give the desired product (HCl salt).
- the product was diluted with aqueous NaHCO3 (10 mL) and extracted with DCM (10 mL x 3).
- Step 2 tert-Butyl 4-[[4-[(3-nitro-6-phenyl-2-pyridyl)amino]phenyl]methyl]piperazine- 1-carboxylate [00187] To a solution of tert-butyl 4-[[4-[(6-chloro-3-nitro-2- pyridyl)amino]phenyl]methyl]piperazine-1-carboxylate (1.0 g, 2.23 mmol) and phenylboronic acid (544 mg, 4.47 mmol) in 1,4-dioxane (10 mL) and H2O (2 mL) were added Pd(dppf)Cl2 (327 mg, 0.446 mmol) and K 2 CO 3 (926 mg, 6.7 mmol).
- Step 3 tert-Butyl 4-[[4-[2-(2-amino-3-pyridyl)-5-phenyl-imidazo[4,5-b]pyridin-3- yl]phenyl]methyl]piperazine-1-carboxylate [00189] To a solution of 2-aminopyridine-3-carbaldehyde (269 mg, 2.21 mmol) and tert-butyl 4- [[4-[(3-nitro-6-phenyl-2-pyridyl)amino]phenyl]methyl]piperazine-1-carboxylate (900 mg, 1.84 mmol) in DMSO (10 mL) was added Na 2 S 2 O 4 (960 mg, 5.52 mmol) at 15 °C.
- the mixture was stirred at 100 °C for 20 hr.
- the reaction mixture was diluted with H 2 O (50 mL) and extracted with DCM (80 mL x 3). The combined organic layers were washed with brine (80 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue.
- Step 4 3-[5-Phenyl-3-[4-(piperazin-1-ylmethyl)phenyl]imidazo[4,5-b]pyridin-2- yl]pyridin-2-amine [00191] A solution of tert-butyl 4-[[4-[2-(2-amino-3-pyridyl)-5-phenyl-imidazo[4,5-b]pyridin-3- yl]phenyl]methyl]piperazine-1-carboxylate (400 mg, 712 ⁇ mol) in HCl/1,4-dioxane (4M, 8 mL) was stirred at 25 °C for 4 hr.
- Step 2 tert-butyl (1-(4-((3-nitro-6-phenylpyridin-2-yl)amino)benzyl)piperidin-4- yl)carbamate
- Step 3 tert-Butyl (1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl) carbamate
- Step 4 3-(3-(4-((4-Aminopiperidin-1-yl)methyl)phenyl)-5-phenyl-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine
- Step 1 Methyl 4-((6-chloro-3-nitropyridin-2-yl)amino)benzoate [00203] To a solution of methyl 4-aminobenzoate (5 g, 33.1 mmol) in DMSO (50 mL) were added 2,6-dichloro-3-nitro-pyridine (7.66 g, 39.7 mmol) and DIEA (12.82 g, 99.2 mmol). The mixture was stirred at 80 °C for 16 hr.
- Step 2 Methyl 4-((3-nitro-6-phenylpyridin-2-yl)amino)benzoate [00205] To a solution of methyl 4-[(6-chloro-3-nitro-2-pyridyl)amino]benzoate (45 g, 146 mmol) and phenylboronic acid (21.4 g, 176 mmol) in 1,4-dioxane (500 mL) and H 2 O (100 mL) were added Pd(dppf)Cl2 (10.7 g, 14.6 mmol) and Cs2CO3 (143 g, 439 mmol).
- Step 3 Methyl 4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzoate [00207] To a solution of methyl 4-[(3-nitro-6-phenyl-2-pyridyl)amino]benzoate (15 g, 42.9 mmol) in DMSO (150 mL) were added 2-aminopyridine-3-carbaldehyde (6.29 g, 51.5 mmol) and Na2S2O4 (15 g, 85.9 mmol). The reaction mixture was heated to 100°C for 16 hr.
- Step 4 (4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)phenyl)methanol
- methyl 4-[2-(2-amino-3-pyridyl)-5-phenyl-imidazo[4,5-b]pyridin-3- yl]benzoate (2.5 g, 5.9 mmol) in THF (25 mL) was added LiAlH 4 (450 mg, 11.9 mmol) at 0 °C. After addition, the resulting mixture was stirred at 25 °C for 2 hr.
- Step 5 3-(3-(4-(Chloromethyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine [00211] To a solution of [4-[2-(2-amino-3-pyridyl)-5-phenyl-imidazo[4,5-b]pyridin-3- yl]phenyl]methanol (2.3 g, 5.9 mmol) in CH2Cl2 (25 mL) was added SOCl2 (2.1 g, 17.5 mmol). The mixture was stirred at 40°C for 1 hr. The reaction mixture was filtered.
- Step 2 2-Hydroxy-4-piperazin-1-yl-benzaldehyde
- tert-butyl 4-(3-formyl-4-hydroxy-phenyl)piperazine-1-carboxylate 190 mg, 621 ⁇ mol
- 1,4-dioxane 1,4-dioxane
- HCl 1,4-dioxane
- 4M 1,4-dioxane
- Step 2 2-Hydroxy-5-(piperazin-1-yl)benzaldehyde
- tert-butyl 4-(3-formyl-4-hydroxy-phenyl)piperazine-1-carboxylate 400 mg, 1.31 mmol
- 1,4-dioxane 2 mL
- 4 mL HCl/1,4-dioxane 4 M
- the mixture was degassed, purged with N2 2.
- the reaction mixture was filtered and the filtered cake was concentrated under reduced pressure to give 2- hydroxy-5-(piperazin-1-yl)benzaldehyde (Intermediate 7, 320 mg, HCl salt).
- Step 1 Benzyl 4-(cyclopropylamino)piperidine-1-carboxylate
- benzyl 4-oxopiperidine-1-carboxylate 500 mg, 2.14 mmol
- CH2Cl2 5 mL
- cyclopropanamine 184 mg, 3.22 mmol, HCl salt
- AcOH (193 mg, 3.22 mmol)
- the mixture was stirred at 25 °C for 1 hr and then NaBH(OAc) 3 (681 mg, 3.22 mmol) was added.
- the resulting mixture was stirred at 25 °C for 16 hr.
- Step 2 Benzyl 4-((tert-butoxycarbonyl)(cyclopropyl)amino)piperidine-1-carboxylate
- benzyl 4-(cyclopropylamino)piperidine-1-carboxylate 580 mg, 2.11 mmol
- H2O 5 mL
- Na2CO3 672 mg, 6.34 mmol
- Boc 2O
- Step 3 tert-Butyl cyclopropyl(piperidin-4-yl)carbamate
- benzyl 4-((tert-butoxycarbonyl)(cyclopropyl)amino)piperidine-1- carboxylate 500 mg, 1.34 mmol
- MeOH MeOH
- Pd/C 150 mg, 10% purity
- the mixture was purged with H 2 three times and stirred at 40 °C under H 2 atmosphere (40 Psi) for 16 hr.
- the mixture was filtered and washed with MeOH (10 mL x 2).
- Step 4 tert-Butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)(cyclopropyl)carbamate
- K 2 CO 3 tert-butyl cyclopropyl(piperidin-4- yl)carbamate (350 mg, 1.46 mmol). The mixture was stirred at 25 °C for 16 hr. The reaction mixture was quenched with H2O (10 mL) at 25 °C, diluted with EtOAc (15 mL) and washed with H 2 O (20 mL x 3).
- Step 5 3-(3-(4-((4-(Cyclopropylamino)piperidin-1-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
- tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b CH 2 Cl 2 (3 of the mixture was adjusted to 8 with saturated NaHCO 3 .
- the mixture was diluted with CH 2 Cl 2 (15 mL), extracted with CH 2 Cl 2 (20 mL x 3).
- Step 2 3-(3-(4-((4-(Ethylamino)piperidin-1-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00237] To a solution of tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)(ethyl)carbamate (320 mg, 530 ⁇ mol) in 1,4-dioxane (3.0 mL) was added 4M HCl in 1,4-dioxane (3.0 mL).
- Step 1 tert-Butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(2-oxo-1,2-dihydropyridin-3-yl)- 3H-imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carboxylate
- 2CO3 470 mg, 1.44 mmol
- Pd(dppf)Cl2 70.4 mg, 2O (1 mL) was degassed and purged with N 2 three times.
- the mixture was stirred at 80 °C for 16 hr under N 2 atmosphere.
- the reaction mixture was filtered at 25°C, diluted with H2O (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.
- Step 2 3-(2-(2-Aminopyridin-3-yl)-3-(4-(piperazin-1-ylmethyl)phenyl)-3H- imidazo[4,5-b]pyridin-5-yl)pyridin-2(1H)-one
- tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(2-oxo-1,2-dihydropyridin- 3-yl)-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carboxylate 200 mg, 346 ⁇ mol
- Step 1 (4-((3-Nitropyridin-2-yl)amino)phenyl)methanol [00247] To a solution of (4-aminophenyl)methanol (10 g, 81.2 mmol) in 1,4-dioxane (150 mL) were added DIEA (31.5 g, 244 mmol) and 2-chloro-3-nitro-pyridine (15.5 g, 97.4 mmol). The mixture was stirred at 100 °C for 16 hr.
- Step 2 (4-(2-(2-Aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3-yl)phenyl)methanol
- 4-((3-nitropyridin-2-yl)amino)phenyl)methanol 10 g, 40.8mmol
- Na 2 S 2 O 4 21.3 g, 122 mmol
- 2-aminopyridine-3-carbaldehyde 5.98 g, 48.9 mmol
- Step 3 3-(3-(4-(Chloromethyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00251] To a solution of (4-(2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3- yl)phenyl)methanol (1.0 g, 3.15 mmol) in CH 2 Cl 2 (10 mL) was added SOCl 2 (3.3 g, 27.6 mmol). The mixture was stirred at 40 °C for 1 hr.
- Step 2 2-Fluoro-6-hydroxy-4-(piperazin-1-yl)benzaldehyde
- HCl 1,4-dioxane (4 M, 231 pressure
- 2-fluoro-6-hydroxy-4-(piperazin-1-yl)benzaldehyde (Intermediate 15, 200 mg, crude, HCl salt) as a yellow solid which was used in the next step.
- Step 2 2-Hydroxy-4-(piperazin-1-yl)-5-vinylbenzaldehyde
- HCl 1,4-dioxane (4 M, 90.2 pressure
- MS: m/z 233.1 [M + H] + .
- Step 2 3-(5-(3,6-Dihydro-2H-pyran-4-yl)-3-(4-(piperazin-1-ylmethyl)phenyl)-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00276] To a solution of tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(3,6-dihydro-2H-pyran-4- yl)-3H-imidazo[4,5-b 25 °C for 3 hr. The mixture was filtrated and concentrated.
- Step 2 Methyl 4-(2-(2-aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5-b]pyridin-3- yl)benzoate
- a mixture of methyl 4-((6-morpholino-3-nitropyridin-2-yl)amino)benzoate (2.94 g, 8.20 mmol), 2-aminonicotinaldehyde (1.10 g, 9.02 mmol), and Na2S2O4 (5.71 g, 32.8 mmol) in DMSO (30 mL) was stirred at 100 °C for 16 hr. The reaction mixture was cooled to room temperature and the pH was adjusted to about 9 with sat.
- Step 3 (4-(2-(2-Aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5-b]pyridin-3- yl)phenyl)methanol
- Step 4 3-(3-(4-(Chloromethyl)phenyl)-5-morpholino-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine
- Step 4 3-(3-(4-(Chloromethyl)phenyl)-5-morpholino-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine
- Step 2 tert-Butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carboxylate
- 2-aminonicotinaldehyde 9 mg, 794 ⁇ mol
- Na 2 S 2 O 4 542 mg, 2.65 mmol
- Step 3 3-(5-Morpholino-3-(4-(piperazin-1-ylmethyl)phenyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine
- tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-morpholino-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carboxylate 270 mg, 473 ⁇ mol
- the mixture was stirred at 100 °C for 16 hr under N2 atmosphere.
- the reaction mixture was filtered at 25°C, diluted with H 2 O (20 mL), and extracted with CH 2 Cl 2 (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure.
- Step 2 3-(2-(2-Aminopyridin-3-yl)-3-(4-(piperazin-1-ylmethyl)phenyl)-3H- imidazo[4,5-b]pyridin-5-yl)benzonitrile
- tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(3-cyanophenyl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carboxylate 240 mg, 409 ⁇ mol
- 1,4-dioxane for 16 hr.
- the reaction mixture was filtered.
- the mixture was stirred at 120 °C for 16 hr under N2 atmosphere.
- the reaction mixture was filtered at 25 °C, diluted with H 2 O (20 mL), and extracted with CH 2 Cl 2 (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.
- Step 2 2-(2-(2-Aminopyridin-3-yl)-3-(4-(piperazin-1-ylmethyl)phenyl)-3H- imidazo[4,5-b]pyridin-5-yl)benzonitrile
- tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(2-cyanophenyl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carboxylate 400 mg, 682 ⁇ mol
- the reaction mixture was filtered.
- Step 2 tert-Butyl 4-((3-methoxy-4-vinylphenyl)amino)piperidine-1-carboxylate [00317] To a solution of tert-butyl 4-((4-bromo-3-methoxyphenyl)amino)piperidine-1- carboxylate (500 mg, 1.3 mmol) and Pd(dppf)Cl2 (95 mg, ) in toluene (10 mL) was added tributyl(vinyl)stannane (2.03 g, 6.4 mmol).
- Step 3 tert-Butyl 4-((4-formyl-3-methoxyphenyl)amino)piperidine-1-carboxylate [00319] To a solution of tert-butyl 4-((3-methoxy-4-vinylphenyl)amino)piperidine-1- carboxylate (800 mg, 2.41 mmol) and K 2 O S O 4 (26.6 mg, ) in THF (9 mL) and H 2 O (3 mL) was added NaIO4 (1.54 g, 7.22 mmol). The mixture was stirred at 25 °C for 1 hr.
- Step 4 2-Methoxy-4-(piperidin-4-ylamino)benzaldehyde
- tert-butyl 4-((4-formyl-3-methoxyphenyl)amino)piperidine-1- 1,4-dioxane 2 mL
- 4M HCl 4M HCl in 1,4-dioxane (2 mL)
- the reaction mixture was concentrated under reduced pressure to give 2-methoxy-4-(piperidin-4-ylamino)benzaldehyde (Intermediate 30, 30 mg, HCl salt) was obtained as a yellow solid.
- Step 1 tert-Butyl 4-(3-bromo-2-methoxybenzamido)piperidine-1-carboxylate [00326] To a solution of tert-butyl 4-aminopiperidine-1-carboxylate (2 g, 9.99 mmol) in DMF (10 mL) were added 3-bromo-2-methoxybenzoic acid (2.31 g, 9.99 mmol), HATU (5.70 g, 14.9 mmol) and DIEA (3.87 g, 29.9 mmol).
- Step 3 tert-Butyl 4-(3-formyl-2-methoxybenzamido)piperidine-1-carboxylate
- tert-butyl 4-(2-methoxy-3-vinylbenzamido)piperidine-1-carboxylate 1.2 g, 3.33 mmol
- H2O 5 mL
- K2OsO4.2H2O 123 mg, 333 4 (2.14 g, 9.99 mmol
- Step 4 3-Formyl-2-methoxy-N-(piperidin-4-yl)benzamide
- tert-butyl 4-(3-formyl-2-methoxybenzamido)piperidine-1-carboxylate 1.1 g, 3.04 mmol
- CH2Cl2 tert-butyl 4-(3-formyl-2-methoxybenzamido)piperidine-1-carboxylate
- the mixture was filtered and the filter cake was concentrated under reduced pressure to give 3-formyl-2-methoxy-N-(piperidin-4-yl)benzamide (Intermediate 32, 600 mg, yield: 67%) as a yellow solid.
- MS: m/z 263.1 [M + H] + .
- Step 2 3-(3-(4-((4-Aminopiperidin-1-yl)methyl)phenyl)-5-morpholino-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine
- reaction mixture was diluted with H2O (200 mL) and extracted with CH 2 Cl 2 (50 mL x 3). The pH of aqueous phase was adjusted to about 8 ⁇ 9 with sat. Na 2 CO 3 (100 mL). The mixture was extracted with EtOAc (50 mL x 6), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
- Step 2 (4-((3-Nitro-5-phenylpyridin-2-yl)amino)phenyl)methanol
- Step 3 (4-(2-(2-Aminopyridin-3-yl)-6-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)phenyl)methanol
- [4-[(3-nitro-5-phenyl-2-pyridyl)amino]phenyl]methanol 15 g, 46.7 mmol
- Na2S2O4 16 g, 93 mmol
- 2-aminopyridine-3- carbaldehyde (6.8 g, 56 mmol). The mixture was stirred at 100 °C for 12 hr.
- Step 4 3-(3-(4-(Chloromethyl)phenyl)-6-phenyl-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine
- [4-[2-(2-amino-3-pyridyl)-6-phenyl-imidazo[4,5-b]pyridin-3- yl]phenyl]methanol 500 mg, 1.3 mmol
- SOCl 2 771 mg, 6.5 mmol
- Step 2 3-(3-(4-((4-(Methylamino)piperidin-1-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
- Step 2 3-(3-(4-((4-(Methylamino)piperidin-1-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
- Step 2 2-Hydroxy-5-(methyl(piperidin-4-yl)amino)benzaldehyde
- tert-butyl 4-((3-formyl-4-hydroxyphenyl)(methyl)amino)piperidine-1- carboxylate 150 mg, ) in CH 2 Cl 2 (2 mL
- 4M HCl 1,4-dioxane(1.68 mL)
- pressure to give 2-hydroxy-5-(methyl(piperidin-4-yl)amino)benzaldehyde (Intermediate 39, 102 mg, HCl salt) as an off white solid, which was used in the next step without further purification.
- Step 1 tert-Butyl 2-(4-formyl-3-hydroxyphenyl)-2,7-diazaspiro[3.5]nonane-7- carboxylate [00381] To a solution of tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate (200 mg, 1.43 mmol) and 4-fluoro-2-hydroxybenzaldehyde (323 mg, 1.43 mmol) in DMSO (2 mL) was added DIEA (553 mg, 4.28 mmol).
- Step 2 2-Hydroxy-4-(2,7-diazaspiro[3.5]nonan-2-yl)benzaldehyde
- tert-butyl 2-(4-formyl-3-hydroxyphenyl)-2,7-diazaspiro[3.5]nonane-7- carboxylate 200 mg, 577 mol
- 1,4-dioxane 2 mL
- HCl 1,4-dioxane
- Step 2 2-Hydroxy-5-(2,7-diazaspiro[4.4]nonan-2-yl)benzaldehyde
- tert-butyl 7-(3-formyl-4-hydroxy-phenyl)-2,7-diazaspiro[4.4]nonane-2- 2Cl2 (2 mL) was added 4M HCl in EtOAc (2 mL). The mixture was stirred at 25 °C for 1hr.
- Step 2 2-Hydroxy-5-(2,6-diazaspiro[3.3]heptan-2-yl)benzaldehyde
- TFA 1.8 g, 13.5 mmol
- the mixture was stirred at 25 °C for 16 hr.
- the reaction mixture was diluted with H2O (10 mL) at 25 °C and extracted with CH 2 Cl 2 (20 mL x 3). The combined organic layers were washed with brine (30 ml), dried over Na2SO4, filtered, and concentrated under reduced pressure.
- Step 2 (R)-3-(3-(4-((2,7-Diazaspiro[4.4]nonan-2-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
- R tert-butyl
- Step 2 1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)azepan-4-amine
- Step 2 tert-Butyl 4-(2-formyl-3-methoxyphenoxy)piperidine-1-carboxylate
- tert-butyl 4-(2-bromo-3-methoxyphenoxy)piperidine-1-carboxylate 1 2 2.
- the reaction mixture was diluted with NH 4 Cl (30 mL) and extracted with EtOAc (50 mL x 3).
- the combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure.
- Step 3 2-Methoxy-6-(piperidin-4-yloxy)benzaldehyde
- HCl 1,4-dioxane (4 M, 0.5 mL).
- the reaction mixture concentrated under reduced pressure to give 2-methoxy-6-(piperidin-4-yloxy)benzaldehyde (Intermediate 87, 160 mg, HCl salt, yield: 99%) as an off white solid which was used directly for next step.
- Step 1 tert-Butyl (S)-(1-(4-nitrophenyl)ethyl)carbamate
- Step 2 tert-Butyl (S)-(1-(4-aminophenyl)ethyl)carbamate
- Step 3 tert-Butyl (S)-(1-(4-((6-chloro-3-nitropyridin-2- yl)amino)phenyl)ethyl)carbamate
- Step 4 tert-Butyl (S)-(1-(4-((3-nitro-6-phenylpyridin-2- yl)amino)phenyl)ethyl)carbamate
- a mixture of tert-butyl (S)-(1-(4-((6-chloro-3-nitropyridin-2- yl)amino)phenyl)ethyl)carbamate (6.1 g, 14.0 mmol), phenylboronic acid (2.04 g, 16.8 mmol), Pd(dppf)Cl2 (1.02 g, 1.40 mmol), Cs2CO3 (13.7 g, 42.0 mmol) in 1,4-dioxane (100 mL) and H2O (10 mL) was degassed and purged with N2 hr under N 2 atmosphere.
- Step 5 tert-Butyl (S)-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)phenyl)ethyl)carbamate
- tert-butyl (S)-(1-(4-((3-nitro-6-phenylpyridin-2- yl)amino)phenyl)ethyl)carbamate (4.34 g, 9.99 mmol)
- 2-aminonicotinaldehyde (1.46 g, 11.9 mmol) in DMSO (40 mL) was added Na 2 S 2 O 4 (3.48 g, 19.9 mmol).
- Step 6 (S)-3-(3-(4-(1-Aminoethyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine
- (S)-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)phenyl)ethyl)carbamate 1.3 g, 2.57 mmol) in CH2Cl2 (10 mL) was added HCl in was concentrated under reduced pressure to give (S)-3-(3-(4-(1-aminoethyl)phenyl)-5-phenyl- 3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (Intermediate 94, 1.2 g, HCl salt, yield: 83
- Step 2 3-(5-(2-Fluorophenyl)-3-(4-(piperazin-1-ylmethyl)phenyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine hydrochloride
- tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(2-fluorophenyl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carboxylate 500 mg, 863 ⁇ mol
- 1,4-dioxane 5 mL
- HCl/1,4-dioxane 4M, 5 mL
- Step 2 3-(5-(4-Fluorophenyl)-3-(4-(piperazin-1-ylmethyl)phenyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine hydrochloride [00511] To a solution of tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(4-fluorophenyl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carboxylate (500 mg, 863 ⁇ mol) in 1,4-dioxane (5 mL) was added HCl/1,4-dioxane (4 M, 5 mL).
- Step 2 Methyl 4-(2-(2-aminopyridin-3-yl)-5-(2-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzoate
- methyl 4-((6-(2-chlorophenyl)-3-nitropyridin-2-yl)amino)benzoate 1.5 g, 3.91 mmol
- 2-aminonicotinaldehyde 525 mg, 4.30 mmol
- the mixture was stirred at 100 °C for 12 hr.
- Step 3 (4-(2-(2-Aminopyridin-3-yl)-5-(2-chlorophenyl)-3H-imidazo[4,5-b]pyridin-3- yl)phenyl)methanol
- Step 3 (4-(2-(2-Aminopyridin-3-yl)-5-(2-chlorophenyl)-3H-imidazo[4,5-b]pyridin-3- yl)phenyl)methanol
- Step 4 3-(3-(4-(Chloromethyl)phenyl)-5-(2-chlorophenyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine
- 4-(2-(2-aminopyridin-3-yl)-5-(2-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)phenyl)methanol 700 mg, 1.64 mmol
- SOCl 2 (1.17 g, 9.82 mmol
- Step 1 Methyl 4-((6-(4-chlorophenyl)-3-nitropyridin-2-yl)amino)benzoate
- Step 2 Methyl 4-(2-(2-aminopyridin-3-yl)-5-(4-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzoate [00525] To a solution of methyl 4-((6-(4-chlorophenyl)-3-nitropyridin-2-yl)amino)benzoate (5 g, 13.0 mmol) and 2-aminonicotinaldehyde (1.75 g, 14.3 mmol) in DMSO (150 mL) was added Na 2 S 2 O 4 (9.07 g, 52.1 mmol). The mixture was stirred at 100 °C for 16 hr.
- Step 3 (4-(2-(2-Aminopyridin-3-yl)-5-(4-chlorophenyl)-3H-imidazo[4,5-b]pyridin-3- yl)phenyl)methanol
- 4-(2-(2-aminopyridin-3-yl)-5-(4-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzoate (2.3 g, 5.05 mmol) in THF (30 mL) was added LiAlH 4 (2.5 M, 2.42 mL) at 0 °C. The mixture was stirred at 25°C for 2 hr.
- Step 4 3-(3-(4-(Chloromethyl)phenyl)-5-(4-chlorophenyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine
- [00529] To a solution of (4-(2-(2-aminopyridin-3-yl)-5-(4-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)phenyl)methanol (1.85 g, 4.32 mmol) in CH 2 Cl 2 (40 mL) was added SOCl 2 (1.54 g, 13.0 mmol) at 0 °C. The mixture was stirred at 40 °C for 3 hr.
- Step 1 tert-Butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(4-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carboxylate [00532] To a solution of Intermediate 98 (1 g, 2.24 mmol), tert-butyl piperazine-1-carboxylate 2CO3 (929 mg, 6.72 mmol).
- Step 2 3-(5-(4-Chlorophenyl)-3-(4-(piperazin-1-ylmethyl)phenyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine
- [00534] To a solution of tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(4-chlorophenyl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carboxylate (550 mg, 923 ⁇ mol) in 1,4-dioxane for 1 hr.
- Step 1 tert-Butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(cyclohex-1-en-1-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carboxylate [00537] 2 O (1 2CO3 (159 mg, 1.15 mmol) and Pd(dppf)Cl2 2.
- Step 2 3-(5-(Cyclohex-1-en-1-yl)-3-(4-(piperazin-1-ylmethyl)phenyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine [00539] To a solution of tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(cyclohex-1-en-1-yl)-3H- imidazo[4,5-b for 3 hr. The mixture was filtrated and concentrated.
- Step 2 2-Hydroxy-4-(4,7-diazaspiro[2.5]octan-4-yl)benzaldehyde
- Step 2 2-Hydroxy-4-(4,7-diazaspiro[2.5]octan-4-yl)benzaldehyde
- Example 1 N-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-4-formyl-3-hydroxybenzamide
- HATU 2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl
- DIPEA 329 mg, 2.55 mmol
- Example 2 N-(4-(2-(2-Aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)-3- formyl-4-hydroxybenzamide [00550] Following the general procedure of Example 1, the reaction of Intermediate 1 (150 mg, 478 ⁇ mol) with 3-formyl-4-hydroxy-benzoic acid (94.5 mg, 567 ⁇ mol) was carried out.
- Example 3 N-(4-(2-(2-Aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)-4- formyl-3-hydroxybenzamide [00552] Following the general procedure of Example 1, the reaction of Intermediate 1 (150 mg, 478 ⁇ mol) with 4-formyl-3-hydroxybenzoic acid (94.5 mg, 567 ⁇ mol) was carried out.
- Example 4 N-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-3-formyl-4-hydroxybenzamide
- EDCI 73 mg, 382 ⁇ mol
- HOBt 52 mg, 382 ⁇ mol
- DIEA 132 mg, 1.02 mmol
- Example 5 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00556] Following the general procedure of Example 4, the reaction of Intermediate 3 (150 mg, 325 ⁇ mol) with 3-formyl-4-hydroxy-benzoic acid (59 mg, 357 ⁇ mol) was carried out.
- Example 6 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde
- Step 6 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde
- Example 7 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-3-formyl-4-hydroxybenzamide [00560] Following the general procedure of Example 4, the reaction of Intermediate 4 (150 mg, 315 ⁇ mol) with 3-formyl-4-hydroxy-benzoic acid (59 mg, 357 ⁇ mol) was carried out.
- Example 8 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-4-formyl-3-hydroxybenzamide [00562] Following the general procedure of Example 4, the reaction of Intermediate 4 (150 mg, 315 ⁇ mol) with 4-formyl-3-hydroxy-benzoic acid (58 mg, 347 ⁇ mol) was carried out.
- Example 9 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)-2-hydroxybenzaldehyde
- DIEA 169 ⁇ L, 971 ⁇ mol
- Intermediate 6 59 mg, 243 ⁇ mol
- Example 10 5-(4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)-2-hydroxybenzaldehyde
- DIEA 0.51 mL, 2.91 mmol
- Intermediate 7 (194 mg, 801 ⁇ mol)
- the mixture was degassed and purged with N 2 2 .
- the reaction mixture was quenched with H2 2Cl2 (10 mL x 3).
- Example 12 N-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-N-cyclopropyl-3-formyl-4-hydroxybenzamide [00570] The mixture was filtered and concentrated under reduced pressure.
- Example 13 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-N-ethyl-3-formyl-4-hydroxybenzamide [00572] hr. The mixture was filtered and concentrated under reduced pressure.
- Example 14 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(2-oxo-1,2-dihydropyridin-3-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde
- Example 15 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(2-oxo-1,2-dihydropyridin-3-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde
- Example 16 4-(4-(4-(2-(2-Aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)-2-hydroxybenzaldehyde
- 2CO3 370 mg, 2.7 mmol. The mixture was stirred at 80 °C for 2 hr. The mixture was diluted with H 2 O (30 mL) and extracted with EtOAc (30 mL ⁇ 2). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure.
- Example 17 4-((4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)(methyl)amino)-2-hydroxybenzaldehyde [00580]
- Step 1 3-(3-(4-(((4-Bromo-3-methoxyphenyl)(methyl)amino)methyl)phenyl)-5-phenyl- 3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00581] 2CO3 The mixture was stirred at 25 °C for 16 hr.
- Step 2 3-(3-(4-(((3-Methoxy-4-vinylphenyl)(methyl)amino)methyl)phenyl)-5-phenyl- 3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
- 3-(3-(4-(((4-bromo-3-methoxyphenyl)(methyl)amino)methyl)phenyl)- 5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine 100 mg, ) and 4,4,5,5- tetramethyl-2-vinyl-1,3,2-dioxaborolane (130 mg, ) in DMF (2 mL) were added Cs2CO3 (165 mg, 507 mol) and Pd(dppf)Cl2 (12.4 mg, ).
- the mixture was degassed, purged with N 2 three times and stirred at 100 °C for 16 hr under N 2 atmosphere.
- the reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (20 mL x 2). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure.
- Step 3 4-((4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)(methyl)amino)-2-methoxybenzaldehyde
- the mixture was stirred at 25 °C for 1 hr.
- the reaction mixture was diluted with H 2 O (50 mL) and extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (50 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure.
- Step 4 4-((4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)(methyl)amino)-2-hydroxybenzaldehyde
- the mixture was degassed, purged with N2 three times, and stirred at 25 °C for 16 hr under N 2 atmosphere.
- the reaction mixture was alkalized with aqueous NaHCO 3 to pH around 9 and extracted with CH 2 Cl 2 (20 mL x 2).
- the combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure.
- Example 18 5-((4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)(methyl)amino)-2-hydroxybenzaldehyde [00589] Following the general procedures described in Example 17, the reactions were carried out using Intermediate 5.
- Example 20 N-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-3-formyl-2-hydroxybenzamide [00593] Step 1: N-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-3-bromo-2-methoxybenzamide [00594] To a solution of Intermediate 2 (1.0 g, 2.6 mmol) and 3-bromo-2-methoxybenzoic acid (880 mg, 4 mmol) in DMF (10 mL) were added DIEA (1.7 g, 13 mmol) and HATU (2.9 g, 7.6 mmol).
- Step 2 N-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2-methoxy-3-vinylbenzamide
- a mixture of N-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-3-bromo-2-methoxybenzamide 1.2 g, 2 mmol
- 4,4,5,5-tetramethyl-2-vinyl-1,3,2- dioxaborolane 610 mg, 4 mmol
- KOAc 389 mg, 4 mmol
- Pd(dppf)Cl 2 and H2O 3 mL) in 1,4-dioxane (12 mL) was degassed and purged with N2 three times.
- Step 3 N-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-3-formyl-2-methoxybenzamide
- N-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2-methoxy-3-vinylbenzamide 4 (581 mg, 2.7 mmol) and K2OsO4.2H2 2O (2 mL). The mixture was stirred at 25 °C for 2 hr.
- Step 4 N-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-3-formyl-2-hydroxybenzamide
- BBr 3 542 mg, 2 mmol
- Example 21 N-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2-formyl-3-hydroxybenzamide
- the reactions were carried out using Intermediate 2.
- After purified by prep-TLC (SiO2, CH2Cl2 : MeOH 15 : 1), N-(4-(2- (2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)-2-formyl-3- hydroxybenzamide (Example 21) was obtained as an off white solid.
- Example 22 2-Amino-N-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-5-formyl-4-hydroxybenzamide
- Step 1 2-Amino-N-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-5-bromo-4-methoxybenzamide
- HATU 291 mg, 764 mol
- DIEA 329 mg, 2.55 mmol
- the mixture was stirred at 25 °C for 16 hr.
- the reaction mixture was diluted with H 2 O (10 mL) and extracted with CH 2 Cl 2 (10 mL x 2). The combined organic layers were washed with brine (10 mL), dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.
- Step 2 2-Amino-N-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-4-methoxy-5-vinylbenzamide
- 2-amino-N-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-5-bromo-4-methoxybenzamide 360 mg, 581 mol
- Pd(dba)2 (16.7 mg, ) in toluene (5 mL) was added tributyl(vinyl)stannane (780 mg, 2.46 mmol).
- the mixture was degassed and purged with N 2 three times and stirred at 110 °C for 16 hr under N 2 atmosphere.
- the reaction mixture was quenched with aqueous KF (10 mL) at 25 °C, diluted with H2O (50 mL), and extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.
- Step 3 2-Amino-N-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-5-formyl-4-methoxybenzamide
- Step 4 2-Amino-N-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-5-formyl-4-hydroxybenzamide [00611] To a solution of 2-amino-N-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-5-formyl-4-methoxybenzamide ( ) in CH 2 Cl 2 (10 mL) was added BBr3 at 0 °C.
- the mixture degassed, purged with N2 three times, and stirred at 25 °C for 16 hr under N2 atmosphere.
- the reaction mixture was alkalized with aqueous NaHCO 3 to pH around 9 and extracted with CH 2 Cl 2 (20 mL x 2).
- the combined organic layers were washed with brine (20 mL x 2), dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.
- Example 23 3-(4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)-2-hydroxybenzaldehyde [00613]
- Step 1 3-(3-(4-((4-(3-Bromo-2-methoxyphenyl)piperazin-1-yl)methyl)phenyl)-5-phenyl- 3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
- the mixture was stirred at 25 °C for 16 hr.
- the reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
- Step 2 3-(3-(4-((4-(2-Methoxy-3-vinylphenyl)piperazin-1-yl)methyl)phenyl)-5-phenyl- 3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
- a mixture of 3-(3-(4-((4-(3-bromo-2-methoxyphenyl)piperazin-1-yl)methyl)phenyl)-5- phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine 230 mg, 356 mol
- 4,4,5,5- tetramethyl-2-vinyl-1,3,2-dioxaborolane (65.7 mg, 427 mol)
- Pd(dppf)Cl 2 26 mg, 35.6 mol
- Cs2CO3 34.8 mg, 1.07 mmol) in 1,4-dioxane (5 mL) and H2O
- the mixture was stirred at 100 °C for 16 hr under N2 atmosphere.
- the reaction mixture was diluted with water (100 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure.
- Step 3 3-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)-2-methoxybenzaldehyde
- 4-(4-(4-(2-methoxy-3-vinylphenyl)piperazin-1-yl)methyl)phenyl)-5- phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine 150 mg, 253 mol
- THF 3-(4-(4-((4-(2-methoxy-3-vinylphenyl)piperazin-1-yl)methyl)phenyl)-5- phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
- NaIO 4 (162 mg, 756 mol
- K 2 O S O 4 9.31 mg, 25.3 mol
- the mixture was stirred at 0 °C for 2 hr.
- the reaction mixture was quenched with Na2SO3 (5 mL) and NaHCO 3 (5 mL) at 0 °C.
- the reaction mixture was diluted with water (100 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure.
- Step 4 3-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)-2-hydroxybenzaldehyde
- BBr 3 To a solution of 3-(4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 2Cl2 (5 mL) was added BBr 3 The reaction mixture was quenched with H 2 O (30 mL) at 25°C, diluted with NaHCO 3 (20 mL), and extracted with EtOAc (3 ⁇ 30 mL).
- Example 24 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)-2-fluoro-6-hydroxybenzaldehyde
- 2CO3 (231 mg, purified by prep-HPLC (column: [water (NH 4 HCO 3 ) - ACN]; B%: 52% - 82%, 18 min)
- 27.4 mg, yield: 13.4% was obtained as a light yellow solid.
- Example 25 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)-5-fluoro-2-hydroxybenzaldehyde [00624] 2CO 3 (231 After purified by prep-HPLC (column: [water (NH4HCO3) - ACN]; B%: 51% - 81%, 18 min), 4- (4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)piperazin-1-yl)- 5-fluoro-2-hydroxybenzaldehyde (Example 25, 16 mg, yield: 7.9% for two steps) was obtained as a yellow solid.
- Example 28 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)-2-hydroxy-5-vinylbenzaldehyde
- 2CO3 167 mg, 1.21 purified by prep-HPLC (column: [water (NH4HCO3) - ACN]; B%: 62% - 92%, 10 min)
- 4-(4-(4- (2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)piperazin-1-yl)-2- hydroxy-5-vinylbenzaldehyde Example 28, 8.9 mg, yield: 5.9% for two steps was obtained as a yellow solid.
- Example 29 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(3,6-dihydro-2H-pyran-4-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde
- 2 Cl 2 0.5 mL were added H2O (10 mL) and extracted with CH2Cl2 (10 mL x 2). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated.
- Example 30 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(3,6-dihydro-2H-pyran-4-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00634] Following the general procedures described in Example 29, the reactions was carried out using Intermediate 20.
- Example 31 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazin-1-yl)-2-hydroxybenzaldehyde
- 2CO3 (246 mg, 1.78 mmol). 2O (1 mL), filtered, and concentrated under reduced pressure.
- Example 32 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde
- Example 33 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00640] Following the general procedures described in Example 32, the reaction was carried out using Intermediate 22.
- Example 34 3-(2-(2-Aminopyridin-3-yl)-3-(4-((4-(3-formyl-4- hydroxybenzoyl)piperazin-1-yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzonitrile [00642] reaction mixture was filtered and concentrated under reduced pressure.
- Example 35 3-(2-(2-Aminopyridin-3-yl)-3-(4-((4-(4-formyl-3- hydroxybenzoyl)piperazin-1-yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzonitrile [00644] Following the general procedures described in Example 34, the reaction was carried out using corresponding starting material 4-formyl-3-hydroxybenzoic acid.
- Example 36 2-(2-(2-Aminopyridin-3-yl)-3-(4-((4-(3-formyl-4- hydroxybenzoyl)piperazin-1-yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzonitrile [00646] To a solution of Intermediate 24 (50 mg, 103 ⁇ mol) and 3-formyl-4-hydroxybenzoic acid (17 mg, 103 ⁇ mol) in DMF (1 mL) were added EDCI (30 mg, 154 ⁇ mol), DIEA (66 mg, 514 ⁇ mol) and HOBt (21 mg, 154 ⁇ mol).
- Example 37 2-(2-(2-Aminopyridin-3-yl)-3-(4-((4-(4-formyl-3- hydroxybenzoyl)piperazin-1-yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzonitrile [00648] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 24.
- Example 38 4-(2-(2-Aminopyridin-3-yl)-3-(4-((4-(3-formyl-4- hydroxybenzoyl)piperazin-1-yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzonitrile [00650] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 25.
- Example 39 4-(2-(2-Aminopyridin-3-yl)-3-(4-((4-(4-formyl-3- hydroxybenzoyl)piperazin-1-yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzonitrile [00652] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 25.
- Example 40 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(3-fluorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00654] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 26.
- Example 41 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(3-fluorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00656] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 26.
- Example 42 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(3-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00658] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 27.
- Example 43 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(3-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00660] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 27.
- Example 44 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(1-methyl-6-oxo-1,6-dihydropyridin- 3-yl)-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde
- DIEA 7.4 mg, 548 mol
- HATU 7.6 mg, 201 mol
- 3-formyl-4-hydroxybenzoic acid quenched with H2O (10 mL) at 0 °C and extracted with CH2Cl2 (10 mL x 3).
- Example 45 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(6-oxo-1,6-dihydropyridin-2-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00664] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 29.
- Example 46 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(6-oxo-1,6-dihydropyridin-2-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00666] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 29.
- Example 47 4-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)amino)-2-hydroxybenzaldehyde [00668]
- Step 1 4-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)amino)-2-methoxybenzaldehyde [00669] 2CO 3
- the reaction mixture was diluted with H 2 O (20 mL) and extracted with EtOAc (20 mL x 2).
- Step 2 4-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)amino)-2-hydroxybenzaldehyde [00671] To a solution of 4-((1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl)amino)-2-methoxybenzaldehyde ( ) in CH2Cl2 (10 mL) was added BBr3 (446 mg, 7.42 mmol) at 0 °C.
- the mixture was degassed and purged with N 2 three times and stirred at 25 °C for 16 hr under N 2 atmosphere.
- the reaction mixture was alkalized with aqueous NaHCO3 to pH to around 9 and extracted with CH2Cl2 (20 mL x 2).
- the combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure.
- Example 48 5-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)amino)-2-hydroxybenzaldehyde [00673] Following the general procedures described in Example 47, the reaction was carried out using Intermediate 5 and Intermediate 31.
- Example 49 N-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-3-formyl-2-hydroxybenzamide [00675] Following the general procedures described in Example 47, the reaction was carried out using Intermediate 5 and Intermediate 32.
- Example 50 3-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl)amino)-2-hydroxybenzaldehyde [00677] Following the general procedures described in Example 47, the reaction was carried out using Intermediate 5 and Intermediate 33.
- Example 51 2-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl)amino)-6-hydroxybenzaldehyde [00679] Following the general procedures described in Example 47, the reaction was carried out using Intermediate 5 and Intermediate 34.
- Example 52 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)-3-formyl-4-hydroxybenzamide [00681] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 35.
- Example 53 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)-4-formyl-3-hydroxybenzamide [00683] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 35.
- Example 54 4-(4-(4-(2-(2-Aminopyridin-3-yl)-6-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazin-1-yl)-2-hydroxybenzaldehyde
- 2CO3 201 mg, 1.5 mmol. The mixture was stirred at 80 °C for 2 hr. The reaction mixture was diluted with H 2 O (20 mL) and extracted with EtOAc (60 mL). The organic layer was washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure.
- Example 55 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl)-3-formyl-4-hydroxy-N-methylbenzamide [00687] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 37.
- Example 56 4-((1R,4R)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl)-2-hydroxybenzaldehyde [00689] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 38.
- Example 57 4-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl)(methyl)amino)-2-hydroxybenzaldehyde [00691] Following the general procedures described in Example 54, the reaction was carried out using Intermediate 5 and Intermediate 39.
- Example 58 (R)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-3-yl)-3-formyl-4-hydroxybenzamide [00693] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 40.
- Example 59 (R)-N-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)pyrrolidin-3-yl)-3-formyl-4-hydroxybenzamide [00695] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 41.
- Example 60 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl)-4-formyl-3-hydroxy-N-methylbenzamide [00697] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 37.
- Example 61 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)azetidin-3-yl)-3-formyl-4-hydroxybenzamide [00699] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 42.
- Example 62 5-(6-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,6-diazaspiro[3.3]heptane-2-carbonyl)-2-hydroxybenzaldehyde [00701] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 43.
- Example 63 (R)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-3-yl)-4-formyl-3-hydroxybenzamide [00703] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 40.
- Example 64 (R)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)pyrrolidin-3-yl)-4-formyl-3-hydroxybenzamide [00705] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 41.
- Example 65 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)azetidin-3-yl)-4-formyl-3-hydroxybenzamide [00707] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 42.
- Example 66 4-(6-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,6-diazaspiro[3.3]heptane-2-carbonyl)-2-hydroxybenzaldehyde [00709] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 43.
- Example 67 5-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[3.5]nonane-2-carbonyl)-2-hydroxybenzaldehyde [00711] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 44.
- Example 68 N-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-7-azaspiro[3.5]nonan-2-yl)-3-formyl-4-hydroxybenzamide [00713] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 45.
- Example 69 N-(2-(4-(2-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2-azaspiro[3.3]heptan-6-yl)-3-formyl-4-hydroxybenzamide [00715] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 46.
- Example 70 N-(2-(4-(2-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2-azaspiro[3.3]heptan-6-yl)-4-formyl-3-hydroxybenzamide [00717] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 46.
- Example 71 4-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[3.5]nonane-2-carbonyl)-2-hydroxybenzaldehyde [00719] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 44.
- Example 72 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-1,4-diazepane-1-carbonyl)-2-hydroxybenzaldehyde [00721] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 47.
- Example 73 4-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-hydroxybenzaldehyde [00723] 2CO3 (151 mg, 1.09 mmol) and NaI (5.46 mg, The reaction mixture was filtered and concentrated under reduced pressure.
- Example 74 5-(8-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,8-diazaspiro[4.5]decane-2-carbonyl)-2-hydroxybenzaldehyde [00725] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 49.
- Example 75 4-(8-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,8-diazaspiro[4.5]decane-2-carbonyl)-2-hydroxybenzaldehyde [00727] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 49.
- Example 76 4-(8-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,8-diazaspiro[4.5]decan-2-yl)-2-hydroxybenzaldehyde [00729] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 50.
- Example 77 5-(9-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-3,9-diazaspiro[5.5]undecane-3-carbonyl)-2-hydroxybenzaldehyde [00731] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 51.
- Example 78 4-(9-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-3,9-diazaspiro[5.5]undecan-3-yl)-2-hydroxybenzaldehyde [00733] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 52.
- Example 79 4-(6-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-hydroxybenzaldehyde [00735] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 53.
- Example 80 5-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[4.4]nonane-2-carbonyl)-2-hydroxybenzaldehyde [00737] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 54.
- Example 81 4-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[4.4]nonane-2-carbonyl)-2-hydroxybenzaldehyde [00739] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 54.
- Example 82 4-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[4.4]nonan-2-yl)-2-hydroxybenzaldehyde [00741] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 55.
- Example 83 5-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[4.4]nonan-2-yl)-2-hydroxybenzaldehyde [00743] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 56.
- Example 84 5-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carbonyl)-2-hydroxybenzaldehyde [00745] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 57.
- Example 85 4-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,8-diazaspiro[4.5]decan-8-yl)-2-hydroxybenzaldehyde [00747] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 58.
- Example 86 5-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[4.5]decane-7-carbonyl)-2-hydroxybenzaldehyde [00749] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 59.
- Example 87 4-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[4.5]decane-7-carbonyl)-2-hydroxybenzaldehyde [00751] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 59.
- Example 88 4-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[4.5]decan-7-yl)-2-hydroxybenzaldehyde [00753] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 60.
- Example 89 4-(6-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-hydroxybenzaldehyde [00755] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 61.
- Example 90 4-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carbonyl)-2-hydroxybenzaldehyde [00757] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 57.
- Example 91 5-(6-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-hydroxybenzaldehyde [00759] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 62.
- Example 92 5-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,6-diazaspiro[3.4]octane-6-carbonyl)-2-hydroxybenzaldehyde [00761] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 63.
- Example 93 4-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,6-diazaspiro[3.4]octane-6-carbonyl)-2-hydroxybenzaldehyde [00763] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 63.
- Example 94 4-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,6-diazaspiro[3.4]octan-6-yl)-2-hydroxybenzaldehyde [00765] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 64.
- Example 95 5-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[3.5]nonane-7-carbonyl)-2-hydroxybenzaldehyde [00767] Following the general procedures described in Example 44, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 65.
- Example 96 4-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[3.5]nonane-7-carbonyl)-2-hydroxybenzaldehyde [00769] Following the general procedures described in Example 44, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 65.
- Example 97 4-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-hydroxybenzaldehyde [00771] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 66.
- Example 98 (R)-5-(7-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,7-diazaspiro[4.4]nonane-2-carbonyl)-2-hydroxybenzaldehyde [00773] Following the general procedures described in Example 44, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 67.
- Example 99 (R)-4-(7-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,7-diazaspiro[4.4]nonane-2-carbonyl)-2-hydroxybenzaldehyde [00775] Following the general procedures described in Example 44, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 67.
- Example 100 (R)-4-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,7-diazaspiro[4.4]nonan-2-yl)-2-hydroxybenzaldehyde [00777] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 68.
- Example 101 (S)-5-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,7-diazaspiro[4.4]nonane-2-carbonyl)-2-hydroxybenzaldehyde [00779] Following the general procedures described in Example 44, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 69.
- Example 102 (S)-4-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,7-diazaspiro[4.4]nonane-2-carbonyl)-2-hydroxybenzaldehyde [00781] Following the general procedures described in Example 44, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 69.
- Example 103 (S)-4-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,7-diazaspiro[4.4]nonan-2-yl)-2-hydroxybenzaldehyde [00783] stirred at 80 °C for 1 hr. The mixture was concentrated under reduced pressure.
- Example 104 (R)-4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2-methylpiperazin-1-yl)-2-hydroxybenzaldehyde [00785] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 71.
- Example 105 (S)-5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2-methylpiperazine-1-carbonyl)-2-hydroxybenzaldehyde [00787] Following the general procedures described in Example 44, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 72.
- Example 106 (S)-4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2-methylpiperazine-1-carbonyl)-2-hydroxybenzaldehyde [00789] Following the general procedures described in Example 44, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 72.
- Example 107 (S)-4-(4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2-methylpiperazin-1-yl)-2-hydroxybenzaldehyde [00791] Following the general procedures described in Example 103, the reaction was carried out using Intermediate 5 and Intermediate 73.
- Example 108 4-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-4,7-diazaspiro[2.5]octan-4-yl)-2-hydroxybenzaldehyde [00793] Following the general procedures described in Example 103, the reaction was carried out using Intermediate 5 and Intermediate 101.
- Example 109 4-(3-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-2-hydroxybenzaldehyde [00795] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 74.
- Example 110 5-(3-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-2-hydroxybenzaldehyde [00797] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 74.
- Example 111 4-(3-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-2-hydroxybenzaldehyde [00799] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 75.
- Example 112 5-(8-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-3,8-diazabicyclo[3.2.1]octane-3-carbonyl)-2-hydroxybenzaldehyde [00801] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 76.
- Example 113 4-(8-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-3,8-diazabicyclo[3.2.1]octane-3-carbonyl)-2-hydroxybenzaldehyde [00803] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 76.
- Example 114 4-(8-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-hydroxybenzaldehyde [00805] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 77.
- Example 115 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)azepan-4-yl)-3-formyl-4-hydroxybenzamide [00807] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 78.
- Example 116 N-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)azepan-4-yl)-4-formyl-3-hydroxybenzamide [00809] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 78.
- Example 117 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)azepan-3-yl)-3-formyl-4-hydroxybenzamide [00811] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 79.
- Example 118 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)azepan-3-yl)-4-formyl-3-hydroxybenzamide [00813] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 79.
- Example 119 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-1,4-diazepane-1-carbonyl)-2-hydroxybenzaldehyde [00815] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 47.
- Example 120 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-1,4-diazepan-1-yl)-2-hydroxybenzaldehyde [00817] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 81.
- Example 121 5-((1S,4S)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl)-2-hydroxybenzaldehyde [00819] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 82.
- Example 122 4-((1S,4S)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl)-2-hydroxybenzaldehyde [00821] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 82.
- Example 123 4-((1S,4S)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-hydroxybenzaldehyde [00823] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 83.
- Example 124 4-((1R,4R)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-hydroxybenzaldehyde [00825] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 84.
- Example 125 4-(5-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,5-diazabicyclo[2.2.2]octane-2-carbonyl)-2-hydroxybenzaldehyde [00827] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 85.
- Example 126 5-(5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,5-diazabicyclo[2.2.2]octane-2-carbonyl)-2-hydroxybenzaldehyde [00829] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 85.
- Example 127 4-(5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)-2-hydroxybenzaldehyde [00831] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 5 and Intermediate 86.
- Example 128 2-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)oxy)-6-hydroxybenzaldehyde [00833] Step 1: 2-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)oxy)-6-methoxybenzaldehyde [00834] HCl salt 2 CO 3 (419 mg, for 2 hr under N2.
- Step 2 2-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)oxy)-6-hydroxybenzaldehyde
- BBr 3 3 (30 mL)
- H 2 O 20 mL
- CH2Cl2 30 mL x 3
- Example 129 4-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)oxy)-2-hydroxybenzaldehyde [00838] Following the general procedures described in Example 128, the reactions were carried out using Intermediate 5 and Intermediate 88.
- Example 130 5-((1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)oxy)-2-hydroxybenzaldehyde [00840] Following the general procedures described in Example 128, the reactions were carried out using Intermediate 5 and Intermediate 89.
- Example 131 5-((3aR,6aS)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-2-hydroxybenzaldehyde [00842] Following the general procedures described in Example 44, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 90.
- Example 132 4-((3aR,6aS)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-2-hydroxybenzaldehyde [00844] Following the general procedures described in Example 44, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 90.
- Example 133 4-((3aR,6aS)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-2-hydroxybenzaldehyde [00846] 2. The mixture was diluted with H 2 O (50 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated.
- Example 134 5-((3aR,6aS)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-2-hydroxybenzaldehyde [00848] Following the general procedures described in Example 133, the reaction was carried out using Intermediate 5 and Intermediate 92.
- Example 135 5-((3aS,6aS)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-2-hydroxybenzaldehyde [00850] Following the general procedures described in Example 44, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 93.
- Example 136 4-((3aS,6aS)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-2- hydroxybenzaldehyde
- the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 93.
- Example 137 2-((4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)oxy)-6-hydroxybenzaldehyde [00854] 2CO3 (712 mg, 2.19 mmol). The mixture was stirred at 30 °C for 3 hr. The reaction mixture was filtered and concentrated under reduced pressure.
- Example 138 4-((4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)oxy)-2-hydroxybenzaldehyde [00856] 2CO3 (237 and concentrated under reduced pressure.
- Example 139 5-((4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)oxy)-2-hydroxybenzaldehyde [00858] To a solution of Intermediate 5 (500 mg, 1.21 mmol), 2,5-dihydroxybenzaldehyde 2CO 3 (1.19 g, 3.64 mmol). The mixture was stirred at 80 °C for 2 hr. The reaction mixture was filtered and concentrated under reduced pressure.
- Example 140 (S)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)phenyl)ethyl)-3-formyl-4-hydroxybenzamide [00860] in CH2Cl2 NaHCO 3 (20 mL) and extracted with CH 2 Cl 2 (50 mL x 3). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
- Example 141 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(2-fluorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00862] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 95.
- Example 142 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(2-fluorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00864] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 95.
- Example 143 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(4-fluorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00866] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 96.
- Example 144 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(4-fluorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00868] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 96.
- Example 145 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(2-chlorophenyl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazin-1-yl)-2-hydroxybenzaldehyde [00870] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 6 and Intermediate 97.
- Example 146 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(4-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazin-1-yl)-2-hydroxybenzaldehyde [00872] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 6 and Intermediate 98.
- Example 147 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(4-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00874] Following the general procedures described in Example 36, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 99.
- Example 148 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(4-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00876] Following the general procedures described in Example 36, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 99.
- Example 149 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(4-chlorophenyl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazin-1-yl)-2-hydroxybenzaldehyde [00878] Following the general procedures described in Example 73, the reaction was carried out using Intermediate 98 and Intermediate 7.
- Example 150 5-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(cyclohex-1-en-1-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00880] Following the general procedures described in Example 44, the reaction was carried out using 3-formyl-4-hydroxybenzoic acid and Intermediate 100.
- Example 151 4-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(cyclohex-1-en-1-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carbonyl)-2-hydroxybenzaldehyde [00882] Following the general procedures described in Example 44, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 100.
- Example 152 4-(9-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-3,9-diazaspiro[5.5]undecane-3-carbonyl)-2-hydroxybenzaldehyde [00884] Following the general procedures described in Example 44, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 51.
- Example 153 4-(6-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,6-diazaspiro[3.4]octane-2-carbonyl)-2-hydroxybenzaldehyde [00886] Following the general procedures described in Example 44, the reaction was carried out using 4-formyl-3-hydroxybenzoic acid and Intermediate 102.
- NanoBRET Target Engagement (TE) Assay is a highly specific and validated cell-based technique for assessing target engagement (Vasta et al., 2018, Cell Chem Biol.25(2):206-214).
- the NanoBRET Target Engagement (TE) Intracellular Kinase Assays are based on the NanoBRET System (Promega Corporation), an energy transfer technique designed to measure molecular proximity in living cells.
- the NanoBRET TE Assays measure the apparent affinity of test compounds by competitive displacement of the NanoBRET tracer compound, which is a cell permeable molecule engineered to be reversibly bound to a NanoLuc® luciferase-kinase fusion expressed in cells.
- NanoBRET assay procedure was used to interrogate the compounds against the full length AKT E17K per manufacturers suggestions. Briefly, HEK-293 cells (ATCC Cat # CRL-1573) were used for transfection purposes using FuGENE HD Transfection Reagent (Promega Cat # E2311). All cells were evaluated for viability prior to transfection and optimization of the transfection was done prior to experimentation. Greater than 95% viability was used for all experiments. Following transfection, cells were washed and resuspended in Opti-MEM. NanoBRET assays were performed in white, 384-well plates (Corning) at a density of 2x10 5 cells/well. All example compounds were prepared as concentrated stock solutions in DMSO (Sigma-Aldrich).
- Example compounds are dissolved in DMSO to make 10 mM stock solution.
- Example compounds were transferred as 40uL of 10 mM stock solution to a 384 pp-plate (LABCYTE, PP-0200) and Apricot liquid handler.
- a Labcyte ECHO 550 compound dispenser was used to facilitate compound transfer directly to cells. Cells were equilibrated for 2 hr with energy transfer probes and example compound prior to BRET measurements.
- the AKTE17K Promega Cat # NV2421
- specific probe NaBRET tracer, Promega Cat # N264B was prepared at a concentration of 20X in tracer dilution buffer (12.5 mM HEPES, 31.25% PEG-400, pH 7.5).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des inhibiteurs d'AKT1, des compositions pharmaceutiques contenant les composés inhibiteurs, et des procédés d'utilisation des composés inhibiteurs d'AKT1 pour le traitement d'une maladie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263376252P | 2022-09-19 | 2022-09-19 | |
US63/376,252 | 2022-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024064026A1 true WO2024064026A1 (fr) | 2024-03-28 |
Family
ID=90455029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/032870 WO2024064026A1 (fr) | 2022-09-19 | 2023-09-15 | Modulateurs d'akt1 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024064026A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011082098A1 (fr) * | 2009-12-30 | 2011-07-07 | The Rockefeller University | Inhibiteurs de lysine et arginine méthyltransférase pour le traitement du cancer |
WO2011082270A2 (fr) * | 2009-12-30 | 2011-07-07 | Arqule. Inc. | Composés imidazopyridinyl-aminopyridine substitués |
WO2014165815A2 (fr) * | 2013-04-04 | 2014-10-09 | University Of Maryland, Baltimore | Composés non-stéroïdiens et stéroïdiens puissants en termes de régulation à la baisse du récepteur des androgènes et d'activité contre le cancer de la prostate |
WO2023168291A1 (fr) * | 2022-03-02 | 2023-09-07 | Terremoto Biosciences, Inc. | Modificateurs covalents de akt1 et leurs utilisations |
-
2023
- 2023-09-15 WO PCT/US2023/032870 patent/WO2024064026A1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011082098A1 (fr) * | 2009-12-30 | 2011-07-07 | The Rockefeller University | Inhibiteurs de lysine et arginine méthyltransférase pour le traitement du cancer |
WO2011082270A2 (fr) * | 2009-12-30 | 2011-07-07 | Arqule. Inc. | Composés imidazopyridinyl-aminopyridine substitués |
WO2014165815A2 (fr) * | 2013-04-04 | 2014-10-09 | University Of Maryland, Baltimore | Composés non-stéroïdiens et stéroïdiens puissants en termes de régulation à la baisse du récepteur des androgènes et d'activité contre le cancer de la prostate |
WO2023168291A1 (fr) * | 2022-03-02 | 2023-09-07 | Terremoto Biosciences, Inc. | Modificateurs covalents de akt1 et leurs utilisations |
Non-Patent Citations (1)
Title |
---|
ASHWELL, M. A. ET AL.: "Discovery and Optimization of a Series of 3-(3-Phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-independent Akt Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 11, 2012, pages 5291 - 5310, XP055076710, DOI: 10.1021/jm300276x * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10131664B2 (en) | Inhibitors of lysine specific demethylase-1 | |
US9822119B2 (en) | Inhibitors of lysine specific demethylase-1 | |
WO2021081375A1 (fr) | Inhibiteurs de kinases raf | |
WO2020198058A1 (fr) | Inhibiteurs de kinases raf | |
US11407737B2 (en) | Inhibitors of RAF kinases | |
EP3962484A1 (fr) | Inhibiteurs de kinases raf | |
EP4327877A2 (fr) | Inhibiteurs doubles de l'atm et de l'adn-pk destinés à être utilisés dans une thérapie antitumorale | |
EP4161656A1 (fr) | Inhibiteurs des kinases réceptrices du facteur de croissance des fibroblastes | |
WO2022081469A1 (fr) | Inhibiteurs de kinases raf | |
WO2017197192A1 (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
WO2021011796A1 (fr) | Inhibiteurs de kinases dépendantes des cyclines | |
WO2019213403A1 (fr) | Inhibiteurs de kinases dépendantes des cyclines | |
AU2021285974A1 (en) | Inhibitors of fibroblast growth factor receptor kinases | |
WO2023070053A1 (fr) | Inhibiteurs de kinases raf | |
WO2024064026A1 (fr) | Modulateurs d'akt1 | |
WO2024102621A1 (fr) | Modulateurs de akt1 | |
WO2024107565A1 (fr) | Modulateurs de akt1 | |
WO2024054512A1 (fr) | Modulateurs de akt1 | |
US11814384B2 (en) | Inhibtors of Raf kinases | |
WO2023224998A1 (fr) | Inhibiteurs de parg | |
WO2024073371A1 (fr) | Modulateurs d'akt1 | |
WO2023114809A1 (fr) | Inhibiteurs de kinase met |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23868817 Country of ref document: EP Kind code of ref document: A1 |